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Chapter One provides a brief introduction to natural products and their applications. 
Several anticancer compounds from plants, marine animals and microorganisms and 
several toxins are listed. Screening for bioactive metabolites, MTT assay and Median 
Lethal Dosage (LD50) are also briefly explained. 
 
Chapter Two is dedicated to the evaluation of Polygonum bistorta (Polygonaceae) for 
anticancer potential using selected cancer cell lines and phytochemical investigations. 
Hexane and chloroform fractions and a few of their sub-fractions showed moderate to 
very good activity against LL2 (Lewis lung carcinoma), P388 (Murine lymphocytic 
leukaemia) and HL60 (Human leukaemia) cancer cell lines. Both active and non-active 
fractions were investigated for their phytochemical constituents. A total of ten 
compounds were isolated including three new compounds, viz. 24(E)-ethylidene- 
cycloartanone, 24(E)-ethylidenecycloartan-3α-ol and 24,31-epoxy-24-ethylcycloartan-
3α-ol. One rarely encountered compound, cycloartane-3,24-dione was also isolated. The 
new compound, 24(E)-ethylidenecycloartanone, was screened for its cytotoxicity against 
P388, HL60, LL2 and WEHI164 cancer cell lines. The Median Lethal Dosage (LD50) of 
the crude extract, hexane and chloroform fractions was evaluated using Swiss albino 
mice of both sexes. 
 
Chapter Three deals with the phytochemical investigations of Eugenia grandis 
Myrtaceae). A total of nine compounds were isolated, including one new compound, 
2α,3β-dihydroxylup-12-en-28-oic acid, a rarely encountered compound, 3β-hydroxylup-
 vi
12-en-28-oic acid and a mixture containing two known compounds viz. arjunolic acid and 
asiatic acid. 
 
Chapter Four is dedicated to the evaluation of sub-fractions of the hexane extract of 
Lasiosphaera nipponica (Basidiomycota) for anticancer potential and identification of the 
chemical constituents. They showed moderate to good activity against P388 and HL60 
cancer cell lines; chemical constituents were identified using GC-MS analysis. One 
known compound, ergosterol peroxide, was isolated in a pure state and was evaluated 
against a four cancer cell lines.  
 
Chapter Five is concerned with the evaluation of Juglans regia, Houttuynia cordata and a 
mixture containing six herbs for anticancer potential using selected cancer cell lines and 
the chemical constituents from Fagraea fragrans. The sub-fractions of the extract 
obtained from the seeds of Juglans regia (Juglandaceae) were evaluated for their 
anticancer potential using P388, HL60, LL2, MCF7 and HepG2 cancer cell lines. One 
known compound, β-sitosterol, was also isolated. Fractions of Houttuynia cordata 
(Saururaceae) and an alcoholic extract of a mixture of six herbs were evaluated for 
anticancer potential using selected cancer cell lines. Fagraea fragrans (Loganiaceae) was 
investigated for chemical constituents. Several known compounds were identified using 
GC-MS analysis. However, only two compounds were isolated in a pure state.  
 
Chapter Six is concerned with the conclusion and future studies on Polygonum bistorta, 
Eugenia grandis, Lasiosphaera nipponica and Fagraea fragrans. Both P. bistorta and L. 
 vii
nipponica can be further investigated for in vivo and/or other in vitro pharmacological 
effects. Similarly, other parts of both E. grandis and F. fragrans can be investigated both 
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1.1.0 General Introduction 
Despite the availability of different approaches for the discovery of therapeutics, natural 
products still remain as one of the best reservoirs of new structural types. Statistics show 
that about 25% of prescription drugs sold in the United States are from natural products, 
while another 25% are from structural modifications of natural products [1]. It was also 
claimed that about 120 prescription drugs are from higher plants. Of the several hundred 
thousand plant species around the world, only a small proportion has so far been 
investigated both phytochemically and pharmacologically. As a single plant may contain 
thousands of constituents, the possibilities of making new discoveries become evident. 
The selection of plant material is thus a crucial factor for the ultimate success of the 
identification of bioactive plant constituents [2]. 
 
Today, the research facilities have enabled researchers to carry out separation of complex 
mixtures into single molecular entities and with the help of modern tools viz. ultraviolet, 
infrared, nuclear magnetic resonance and mass spectrometry, a large number of 
individual compounds from any one plant can be identified unambiguously in a very 
short period of time. These facilities together with the advancements in molecular 
biology provide significant improvements in natural product research which is becoming 





1.1.1 Natural products and their applications 
The term natural products refers to secondary metabolites, small molecules (mol.wt. < 
2000 amu) produced by an organism and these metabolites are not strictly necessary for 
the survival of the organism. Natural products include: (1) an entire organism, (2) part of 
an organism, (3) an extract of an organism or part of an organism and exudates and (4) 
pure compounds (e.g. alkaloids, coumarins, flavonoids, glycosides, xanthones, lignans, 
phenylpropanoids, isoprenoids, sugars, etc.) isolated from plants, animals or 
microorganisms [4]. Many of these compounds show a variety of biological and 
pharmacological activities and some of these compounds are essential for everyday life, 
both for humans and animals.  
 
Alkaloids 
The term ‘alkaloid’, is generally limited to organic bases formed in plants. On the whole, 
alkaloids are very poisonous, but are used medicinally in very small quantity. Morphine 
(1) is an alkaloid found in opium. It is one of the most widely used naturally occurring 
narcotics in medical treatment and has been prescribed for the relief of moderate to 
severe pain. Codeine (2) is used as an antitussive and is generally accepted as the 
standard antitussive against which new antitussive medications are compared [5]. 
Quinine (3) is another alkaloid isolated from the bark of Cinchona species.  It has been 
used for the treatment of malarial fever. 
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Terpenoids 
The diverse, widespread and exceedingly numerous family of natural products 
constructed from five carbon building-units and so comprising compounds with C5, C10, 
C15, C20, etc. skeletons are synonymously termed terpenoids or isoprenoids, with the 
important subgroup of steroids sometimes singled out as a class in its own right [6]. 
These compounds are typically found in all parts (i.e. seed, flowers, foliage, roots and 
wood) of higher plants and also occur in mosses, liverworts, algae and lichens. Some are 
of insect or microbial origin. 
 
Monoterpenoids play an important role in chemical ecology. For example, 1,8-cineol (4) 
and camphor (5) are emitted by assorted plants like eucalyptus and sagebrush and inhibit 
germination and development of seeds of competing species [7]. Yet others act as 
attractants to insect pollinators or repellants of insect or larger predators.  
O
                   
O
 
                                                    (4)                          (5) 
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Sesquiterpenoids exhibit a rich variety of biological properties. Their pharmacological 
properties have also ensured their frequent use in folk medicine. The most famous is α-
santonin (6) which is widely used to combat intestinal worms [8]. Hernandulcin (7) 










(6)                                                 (7) 
Abrusoside sweeteners, which are based on a cycloartane skeleton, are of approximately 
equal sweetness potency to that of the widely used natural product sweetener glycyrrhizin 
(8), an oleanane-type triterpenoid [9]. Abrusoside B (9) isolated from Abrus precatorius 





































Steroids are mostly familiar for their role as hormones, e.g. testosterone (10) and 
progesterone (11). Steroids, such as cortisone (12), are most often used as anti-













             (10)                                        (11)                                      (12) 
A large number of commercially and medicinally valuable steroids available today are 
made by semi-synthetic preparation. 
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Flavonoids 
Flavonoids are another major class of compounds, whose structure is based on flavone 
(13). They are also widely distributed in the plant kingdom and exert a variety of 







                                                                  (13) 
Microorganisms are a prolific source of structurally diverse bioactive metabolites and 
have yielded some of the most important products of the pharmaceutical industry. These 
include: antibacterial agents, such as the penicillins (from Penicillium species), 
cephalosporins (from Cephalosporium acremonium), aminoglycosides, tetracyclins and 
polyketides (all from Streptomyces species) [10]; cholesterol lowering agents, such as 
mevastatin and lovastatin (from Penicillium species) [10]; immunosuppressive agents, 
such as cyclosporins and rapamycin (from Streptomyces species) [10]. Manoalide, 
isolated from the marine sponge, Luffarriella variabilis, shows potent anti-inflammatory 
activity.  The pseudopterosins, isolated from Pseudopterogorgia elisabethae, possess 
significant analgesic and anti-infammatory activities.  
 
1.1.2 Pharmacology 
The interaction of chemical agents with biological systems, how they affect the various 
tissues and their mechanism of actions are studied in pharmacology. Many natural 
products have pharmacological significance.  
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Toxins  
As mentioned earlier alkaloids (plant origins) are the most familiar toxic compounds.  
However, some animals also serve as a potent source of toxic compounds. For example, 
histrionicotoxin (14), a spirocyclic piperidine, has been extracted from small brightly 
coloured frogs, Dendrobates histrionicus. The spirocyclic core is unique in the world of 
natural products and the cis-enyne moiety is also a very unusual feature in the natural 
product kingdom.  
HO HN
 
                                                                 (14) 
When the frogs are kept in captivity, the level of the toxins that they produce is severely 
diminished and in most species not produced at all. This has led to the assertion that the 
toxins are somehow introduced into the frog via diet or by some other outside influence.  
Batrachotoxin, homobatrachotoxin, conatoxins, tetrodotoxin and epibatidine are some 
other examples of toxins derived from animals. Patulin (15), zearalenone (16), aflatoxin 
B1 (17), atropine (18), psoralene (19), vomitoxin (20), 3,4-dihydroxyphenylalanine (21) 
and sporodesmin (22) are some examples of plant-or fungi-derived toxins [11-16]. 
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Botulinum toxin-a Clostridium botulinum 
 
Bacterium 0.00003 
Tetanus toxin Clostridium tetani 
 
Bacterium 0.0001 
Ricin Ricinus communis 
 
Castor Bean Plant 0.02 
Diphtheria toxin Corynebacterium diphtheriae 
 
Bacterium 0.3 
Koki toxin  Phyllobates bicolor 
 
Poison Arrow Frog 2.7 
Tetrodotoxin Sphaeroides rubripes 
 
Puffer Fish  8 
Saxitoxin Aphanizomenon flos-aquae 
 
Cyanobacterium 9 
Cobra toxin Naja naja 
 
Cobra 20 
Nodularin Nodularia spumigena 
 
Cyanobacterium 30-50 
Microcystin-LR Microcystis aeruginosa 
 
Cyanobacterium 50 
Anatoxin-a Anabaena flos-aquae 
 
Cyanobacterium 200 
Microcystin-PR Microcystis aeruginosa 
 
Cyanobacterium 300-600 
Curare Chrondodendron tomentosum 
 




Strychnine Strychnos nux-vomica 
 
Plant 500 
Amatoxin Amanita phalloides 
 
Fungus 600 
Muscarin Amanita muscaria 
 
Fungus 1100 
Phallotoxin Amanita phalloides 
 
Fungus 1800 
Glenodin Peridinium polonicum 
 
Dinoflagellate Alga  2500 
 




Cancer in its many diverse forms is a most insidious disease and represents the second 
major cause of death [17]. The word cancer actually refers to over 100 different diseases, 
but in all cases, certain body cells multiply in an abnormal and unregulated manner. If 
normal cells begin to grow abnormally and reproduce too rapidly, a mass of abnormal 
cells eventually develops. This is called a tumour. The tumour cells localise at the site of 
the origin in the body and if they multiply slowly the tumour is called benign. Benign 
tumours such as cysts, warts, moles and polyps do not spread to other parts of the body 
and are not life threatening. Benign tumours can be removed by surgery and will not re-
grow after surgical excision; thus the victims will recover fully from the tumours. On the 
other hand malignant tumours (called cancers) are composed of cells that grow rapidly 
and invade other normal tissues.  
 
Cancers are medically classified according to the organ or kind of tissue in which they 
originate. Four major categories of cancers are carcinomas, sarcomas, leukaemias and 
lymphomas [18]. Within these major categories are numerous subgroups that generally 
describe the organ in which the cancer originates such as adenocarcinoma of the stomach 
or oat cell carcinoma of the lung.  
 
Recently, pharmacological manipulations on inhibiting tumour cell growth and the 
antiproliferation of malignant cells through induction of apoptosis (or suicidal cell death) 
have been recognised as a novel strategy for the identification and screening of potential 
chemotherapeutic agents.   
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1.1.3 Natural products in the treatment of cancer 
Plant sources 
The anticancer principles, vinblastine (23) and vincristine (24), are alkaloids obtained 
from the periwinkle plant, Catharanthus roseus. This is one of the most successful higher 
plant materials used in cancer chemotherapy. The above mentioned anticancer principles 
have now been extracted commercially for the treatment of leukaemia [19-27]. 
 
Taxol® (25) is a complex polyoxygenated diterpenoid. It was isolated from the bark of 
the Pacific yew tree (Taxus brevifolia). The US Food and Drug Administration (FDA) 
approved taxol for the treatment of ovarian and breast cancers. The natural source, the 
Pacific yew tree, is an environmentally protected species, which is also one of the slowest 
growing trees in the world. Isolation of the compound, which is contained in the bark, 
involves killing the trees and the quantities available are small.  It would take six 100-






















                                       (25)                                                                   (26)     
However, a closely related analogue of taxol, called baccatin III (26) was discovered in 
the needles and twigs of the European yew tree (Taxus baccata) and other different types 
of yews. As the needles are quickly replenishable by the trees, harvesting large quantities 
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has little effect on the population of yew trees. Baccatin III (26) was chemically modified 
to form taxol.  Methods of total synthesis of taxol take more than 30 steps with less than 
0.05% yield [28-30]. This is not considered commercially viable. 
 
CamptothecinTM (30) is a quinoline alkaloid, isolated from the Chinese ornamental tree, 
Camptotheca acuminate. Topotecan (TPT), irinotecan (CPT-11), 9-aminocamptothecin 
and 9-nitrocamptothecin, were semi-synthetically derived from camptothecin [31]. 
Camptothecin and its derivatives are active against carcinomas of stomach, head, neck 
and bladder. Both TPT and CPT-11 have been approved for treating colorectal and 
ovarian cancers.  
Epipodophyllotoxin (30a) was isolated as the active antitumour agent from the roots of 
the genus Podophyllum. These plants possess a long history of medicinal use by early 
American and Asian cultures [32]. Etoposide and teniposide are two clinically active 
agents, which are semi-synthetic derivatives of epipodophyllotoxin. Some cytotoxic 



















Some cytotoxic compounds obtained from plants [33]. 
 
 
Name   
 





Vincristine (24)                     
 
Catharanthus roseus         Indole alkaloid 
Taxol® (25) Taxus brevifolia                 Diterpene alkaloid 
 
Emetine                              
 
Cephaelis acuminata           Isoquinoline alkaloid 
Maquiroside A  
 
Kamebanin                      
 
Maquira calophylla  
 




Lariciresinol        
 
Wilkstroemia elliptica        Lignan 
3’,4’-Deoxypsorospermin      
 
Psorospermum febrifugum   Xanthone 
Larreantin   
 
Allamandin (27)    
 
Larrea tridentata  
 








Cudrania cochinchinensis   
 


















CamptothecinTM (30)  
 
Camptotheca acuminata  Quinoline alkaloid 





















































                                   (24)                                                      (28)     





















                                                                     (31) 
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Marine sources  
The marine environment is a rich source of bioactive compounds, many of which belong 
to totally novel classes not found in terrestrial sources [34]. The first marine-derived 
compound to enter clinical trials is didemnin B (31a), isolated from the tunicate, 
Trididemnum silidum [35]. Ecteinascidin 743 (31b), a metabolite produced by another 
tunicate Ecteinascidia turbinata, has significant in vivo activity against the murine B16 

















































Bryostatins are a group of novel macrocyclic lactones derived from Bugula neritina, a 
marine invertebrate. More than 13 different but structurally closely related compounds 














                                                                        (32) 
Studies showed that bryostatin 1 (32) has significant antineoplastic activity against 
lymphomas, leukaemia, melanoma and breast cancer cell lines. Preliminary results of 
phase I studies had also supported these observations [42]. It has subsequently been 
investigated extensively in phase II clinical trials as a single agent. The status of some 
cytotoxic natural products obtained from marine sources in clinical and preclinical trials 
















Status of some cytotoxic natural products obtained from marine sources in clinical and 
preclinical trials [43-71]. 
 
 
Name                                 
 
 
Source                     
 
Status 
Bryostatin 1 (32)      Bugula neritina                  
 
Phase II 




Kahalalide F  
Dolabella auricularia  
 
Micromonospora Marina  
 













Jaspis sp.  
 















Salicylihalimides A  
 








Aplidium albicans   Phase II 
Ecteinascidin 743         
 
Ecteinascidia turbinate  Phase II/III 
ES-285 (spisulosine)  
 
Spisula polynyma  Phase I 





Arnastarin                               
   
Peloruside A 
 















Clinically useful anticancer microbial agents include daunomycin-related agents, 
daunomycin itself, doxorubicin (Adriamycin®), idarubicin, epirubicin, the glycopeptidic 
bleomycins A2 and B2, mitomycin C, mithramycin etc. All were isolated from various 
Streptomyces species. Other clinically active agents isolated from Sreptomyces include 
streptozocin and deoxycoformycin. 
 
Microbial metabolites in past and present clinical trials include acivicin, aclacinomycin, 
deoxyspergualin, echinomycin, fostriecin, 17-hydroxystaurosporine (UCN-01), 
menogaril, porfiromycin, quinocarmycin and rhizoxin. Microbial products predominate 
amongst the agents under development by the Division of Cancer Treatment and 
Diagnosis of the NCI. These include FR-901228, a novel bicyclic depsipeptide isolated 
from a Chromobacterium violaceum strain and derivatives of quinocarmycin (DX-52-1), 
spicamycin (KRN-500), tetracycline (COL-3), rapamycin and rebeccamycin. Recent 
exciting discoveries are the epothilones isolated from myxobacteria [72]. This class of 
compounds has been shown to act by a similar mechanism of action as paclitaxel and 
could complement the taxanes as chemotherapeutic agents. 
 
Natural products for the inhibition of protein kinases 
Recently, the emphasis in cancer drug discovery has focused on novel compounds that 
target protein kinases. Compounds that target the inhibition of Cyclin Dependent Kinases 
(CDKs) are particularly attractive from the perspective of anticancer drug design.  
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Flavopiridol (33) is a semi-synthetic flavone derived from rohitukine, an alkaloid isolated 
from a plant indigenous to India, Dysoxylum binectarieferum. The National Cancer 
Institute (NCI) identified flavopiridol as a potent antiproliferative compound against all 








                         
                                                             (33)          
Staurosporine (34) is a natural product originally isolated from the bacterium 
Streptomyces staurosporeus and found to be a nonspecific inhibitor of many kinases 
causing cell cycle arrest in G1 and G2 phases in different cell types. It has significant 















                                       (34)                                                         (35) 
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UCN-01 (17-hydroxystaurosporine), (35) isolated from a Streptomyces species, is a 
naturally occurring derivative of staurosporine. It is relatively more selective for CDKs 
(CDK1, 2 and 4) and PKC (Protein Kinase C), although many kinases are also affected. It 
possesses significant antiproliferative activity in several human tumour cell lines and 
tolerable toxicity profile.                                                      
1.1.4 Screening for bioactive metabolites 
The screening of organisms for bioactive metabolites requires a multidisciplinary 
approach, involving chemists, pharmacologists, biochemists, etc. The rapid progress in 
the field of bioactive metabolites is due in large part to the utilisation of bioassay-guided 
fractionation techniques. Many factors can complicate matters when using bioassay-
guided fractionation. For example, in the isolation of leurosine, a dimeric indole alkaloid 
related to vinblastine, the crude alkaloid fraction showed no in vitro activity against the 
P1534 leukaemia system, but the pure alkaloid showed pronounced cytotoxicity in the 
same test. On the other hand, fractionation of the extracts from Combretum caffrum was 
complicated by loss of in vivo activity. Modification of the extraction of a new batch of 
the plant eventually led to the isolation of the antineoplastic combretastatin A-1. 
Cytotoxic assay (MTT Assay) 
Cytotoxic assays are widely used particularly in the field of new drug development. Use 
of a tetrazolium dye [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
(MTT)] to measure the cell number was first reported in the early 1980’s [75]. National 
Cancer Institute (NCI) evaluated MTT-dye reduction as a possible endpoint in a rapid 
screening assay [76]. Cells in exponential phase of growth are exposed to a cytotoxic 
 21
drug. Surviving cell numbers are then determined indirectly by MTT dye reduction. MTT 
is a yellow water soluble tetrazolium dye that is reduced, by live but not dead cells, to a 
purple formazan product that is insoluble in aqueous solutions [77]. The amount of MTT- 
formazan produced can be determined spectrophotometrically once solubilised in a 
suitable solvent. 
 
The compound obtained from either natural sources or entirely synthetic routes is 
screened for cytotoxic activity in vitro and in vivo. Once the screening process has been 
completed, the compound should be properly pharmaceutically-formulated and 
subsequently subjected to human phase I, II and III studies [78,79]. For initial screening, 
dimethylsulfoxide (DMSO) has been used as a suitable solvent with the restriction that it 
is applicable only to hydrophilic compounds. After the identification of paclitaxel (Trade 
name: Taxol®) as the active ingredient in the crude extract of the bark of the Pacific Yew 
tree, Taxus brevifolia, against several murine tumours [80], further development was 
suspended for more than a decade due to problems associated with the solubilisation of 
the compound. Paclitaxel is highly hydrophobic in nature and is insoluble in DMSO. 
Cremophor EL (CrEL) (36) has been suggested as a solvent for hydrophobic compounds. 
CrEL is produced by the reaction of castor oil with ethylene oxide at a molar ratio of 1:35 
[81]. Castor oil is a colourless or pale yellow oil obtained from the seeds of Ricinus 
communis, with an extremely high viscosity and consists of highly variable compositions, 







(x+y+z ~ 35)                                        
(36) 
CrEL is now being used as a vehicle for the solubilisation of a wide variety of 
hydrophobic drugs, including anaesthetics, photosensitisers, sedatives, immuno- 
suppressive agents and anticancer drugs [82]. In contrast to earlier reports, CrEL is not an 
inert vehicle, but exerts a range of biological effects, some of which have important 
clinical implications. CrEL alone has shown cytotoxic effect at high concentrations in 
vitro [83,84].      
 
1.1.5 Median Lethal Dosage (LD50) 
Investigation of the acute toxicity is the first step in the toxicological investigations of an 
unknown substance. The index of the acute toxicity is the Median Lethal Dosage (LD50). 
LD50 is a dosage that will cause a death of fifty percent of the experimental animals. 
However, LD50 should not be regarded as a biological constant, since different results are 
obtained on repetition or when the determinations are carried out in different laboratories 
[83,85]. To determine whether a chemical substance or an extract was very toxic, toxic, 
and less toxic or whether the toxic effects are of no significance, it is desirable to have a 
test. Thus, a means of determining the likelihood of death, as exactly as possible, was 
sought [86]. Moreover, even if LD50 could be measured exactly and reproducibly, the 
knowledge of its precise numerical value would barely be of practical importance, 
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because an extrapolation from the experimental animals to humans is hardly possible. 
The acute toxicity should be tested in two steps. 
1. Different doses are administered to animals to establish the toxic effects. 
2.  Based on the result, further specific doses are administered to calculate LD50. 
The use of single animal in each group can lead to false assessment when, by chance, the 
animal in the non-toxic range dies or in the toxic range survives. For this reason it is 
proposed that at least three animals in each group should be used to determine the toxic 
range. The result of this test is used as a basis for selecting the subsequent doses. The 
following assumptions are made with respect to the subsequent dosage schedules. 
1. Substances with LD50 values less than 1mg/kg (amount of substance/body weight) 
are very toxic; it is not so important to calculate the LD50 exactly. 
2. LD50 values greater than 5,000 mg/kg are of no practical interest. 
3. An approximate figure for the LD50 is usually adequate to estimate the risk of 












Isolation, characterisation and evaluation of Polygonum bistorta 
(Polygonaceae) for anticancer potential using selected cancer cell lines 
2.1.0 Introduction to Polygonaceae Family  
The Polygonaceae are herbs, shrubs or trees comprising about 30 genera and 1,000 
species. The leaves are simple, alternate or rarely opposite and usually stipulate. Many 
species have ocreas at their stem’s nodes. Ocrea is a sheath developed from stipules at the 
attaching leave’s bases. Some ocreas have mildly hairy fringes. The infloresences (flower 
heads) are conspicuous, but the actual flowers are usually tiny and with no petals. The 
flowers are actinomorphic, usually small and are bisexual or occasionally unisexual.  
 
Many compounds have been reported from Polygonaceae family. Quercetin (37), 
rhamnetin (38) and quercetin-3-O-D-glucopyranoside (39) were reported from Antigonon 
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Emodin (40), rhein (41), chrysophanol (42) and physcion (43) were isolated from 










                     (40)  R1 = OH; R2 = Me                             (42) R = H    
                     (41)  R1 = H; R2 = COOH                          (43) R = MeO    
5,6,7,4'-Tetramethoxyflavanone (44), 6-methoxyplumbagin (45), oleanolic acid (46) and 
β-sitosterol (47) were reported from Polygonum aviculare [90]. Danilol (48) was reported 
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                        (46)                                                                         (47) 
5,4'-Dimethoxy-6,7-methylenedioxyflavone-3-O-D-xylopyranoside (viviparum A) (49) 
and 3'-hydroxy-5,4'-dimethoxy-6,7-methylenedioxyflavone-3-O-D-xylopyranoside 
(viviparum B) (50) were reported from Polygonum viviparum [92]. 














                                                   (49)  R = H;   (50) R = OH                                                
Flavonoid compounds and their glycosides were isolated from the dried leaves of 
Polygonum hydropiper (Laksa leaves) [93]. Limonoids, polygonumin A (51) and 
polygonumin B (52), together with four other limonoids, deacetylnomilin, nomilin, 
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                                                       (52)  R = (Z) - feruloyl    
                                                                          
A stilbene compound, 2-carboxy-3,5-dimethoxy-E-stilbene (persilben) (53) was isolated 
from Polygonum persicaria [95]. A flavonoid compound (54) was isolated from 
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A flavonoid compound (55) was isolated from Fagopyrum tataricum [97]. Diesters of 2, 
3-dihydroxyisodrimeninol (56-59) and flavonoid compounds were reported from 
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Steroids, zhonghualiaoine I (60), zhonghualiaoine II (61), cyclobutane compounds (62, 
63) and a flavanonol (64), were reported together with some known compounds from 
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The flowers of Polygonum plebejum contained oleanolic acid (46), betulinic acid (65), 
3β-friedelinol (66) and β-sitosterol (47) [102].  
HO
COOH
              
HO
 
                       (65)                                                                                  (66)                                    
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                                                                  (67) 
Polygonum vaccinifolium, Rheum palmatum, Rheum sp., Rumex alpinus, Rheum 
rhaponicum, Eriogonum inflatum (Desert trumpets), Eriogonum umbellatum (Sulfur 
flower), Pterogonum alatum (Winged buckwheat), Stenogonum salsuginosum, 
Polygonum heterophyllum,  Coccoloba pubescens, Polygonum amphibium, Lapathum 
alpinum, Lapathum aquaticum, Lapathum sylvestris, Polygonum divaricatum, 
Polygonum convolvulus (Black bindweed), Rumex albescens, Fagopyrum esculentum, 
Polygonum aubertii, Polygonum cuspidatum, Polygonum maritimum, Polygonum 
thumbergii, Eriogonum compositum (Northern buckwheat), Eriogonum sp., (Wild 
buckwheat), Homalocladium platycladum (Ribbon bush), Muehlenbeckia axillaries etc. 
are some other species that belong to the Polygonaceae family. 
 
2.1.1 Introduction to Polygonum bistorta 
Polygonum bistorta, commonly known as Bistort or Snakeroot, belongs to the 
Polygonaceae family. It is one of the strongest herb astringents. It is excellent for the 
treatment of cholera, diarrhea and dysentery. When applied to a wound, it can stop 
bleeding. It has been used in traditional Chinese medicine as a remedy for smallpox, 
measles, pimples, jaundice, insect stings, snake bites and expelling worms. It is also taken 
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for the treatment of a wide range of complaints including cystitis, irritable bowel 
syndrome, peptic ulcers and ulcerative colitis.   
2.1.2 Previously reported chemical constituents from P. bistorta 
Catechin (68), epicatechin (69), flavonoids (37, 38, 70-75), aromatic compounds (31, 76-
85), flavonoid glycosides (39, 86-90), sitosterols and a few pentacyclic triterpenoids (91, 
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As far as the biological acitivities of this plant were concerned, it was reported that the 
ethanolic extract caused strong anti-inflammatory effect [104]; 5-glutinen-3-one 
(alnusenone) (91) and friedelinol (92) were identified as active constituents for such 
effect [105]. It was also reported that the aqueous extract strongly inhibits the 






2.2.0 Results and Discussion  
2.2.1 Evaluation of P. bistorta for anticancer potential using selected cancer cell lines 
We have evaluated the chloroform and hexane fractions and their sub-fractions of 
rhizomes of P. bistorta for their anticancer potential using selected cancer cell lines in 
culture. Both the chloroform and hexane fractions and a few of their sub-fractions 
showed moderate to very good activity against P388, HL60 and LL2 cancer cell lines. 
The results are summarised in Tables 4 and 5. 
Table 4 
Cytotoxicity (IC50 values) of hexane fraction and its sub-fractions (A-E) against murine 
and human cancer cell lines in culture. 
_______________________________________________________________ 


















Hexane fraction <10 80.6 >100 17.8 72.0 62.4 
 
A 60.8 >100 80.8 72.0 >100 >100 
 
B 40.8 74.3 64.8 91.2 65.6 >100 
 
C 16.2 63.6 82.1 18.6 64.8 <10 
 
D 50.2 52.3 >100 78.8 40.8 75.0 
 
E 27.6 70.5 >100 63.6 92.6 19.4 
 
 
P338: Murine lymphocytic leukaemia; HL60: Human leukaemia; MCF7: Human breast cancer; 
LL2: Lewis lung carcinoma; HepG2: Hepatocellular carcinoma; J82: Bladder transitional 
carcinoma; IC50 values are expressed in μg/mL; IC50 values less than 30 μg/mL are considered 
active; NT-Not tested; No. of replicates, n = 8 for each concentration; Hexane fraction was 
obtained from the first batch of plant materials (600g); Sub-fractions A-E, were obtained from the 
second batch of plant materials (12kg); 6-Mercaptopurine (6MP) was used as positive control for 
P388 cancer cell lines; Doxorubicin was used as positive control for MCF7 cancer cell lines. 
Positive controls were not maintained throughout experiments. The experiments were conducted 
over a period of time and the availability of cell line concentrations varied at each time; positive 
controls were omitted when there was shortage. The 50% inhibitory concentrations (IC50) were 
measured by MTT assay after 3-days culture. 
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Table 5 
Cytotoxicity (IC50 values) of chloroform fraction and its sub-fractions against murine and 
human cancer cell lines in culture. 
   ____________________________________________________________________  





















<10 78.2 >100 <10 66.6 52.3 NT 
 
F 65.4 >100 70.4 76.0 >100 90.8 NT 
 
G 51.8 90.4 >100 19.4 >100 <10 NT 
 




>221 NT NT >221 NT >221 >221 
 
 
P338: Murine lymphocytic leukaemia; HL60: Human leukaemia; MCF7: Human breast cancer; 
LL2: Lewis lung carcinoma; HepG2: Hepatocellular carcinoma; J82: Bladder transitional 
carcinoma; WEHI164: Murine fibrosarcoma; IC50 values are expressed in μg/mL; IC50 values less 
than 30 μg/mL are considered active; *Pure compound = 24(E)-ethylidenecycloartanone (93); For 
the pure compound, 24(E)-ethylidenecycloartanone (93), the IC50 values are expressed in μM; 
NT-Not tested; No. of replicates, n = 8 for each concentration; Chlorofrom fraction was obtained 
from the first batch of plant materials (600g); Sub-fractions F-H, were obtained from the second 
batch of plant materials (12kg); 6-Mercaptopurine (6MP) was used as positive control for P388 
cancer cell lines; Doxorubicin was used as positive control for MCF7 cancer cell lines. Positive 
controls were not maintained throughout experiments. The experiments were conducted over a 
period of time and the availability of cell line concentrations varied at each time; positive controls 
were omitted when there was shortage. The 50% inhibitory concentrations (IC50) were measured 
by MTT assay after 3-days culture. 
 
 
The hexane fraction of P. bistorta (obtained from the first batch of plant materials, 600g) 
was screened against LL2 (Murine Lewis lung carcinoma), HL60 (Human leukaemia), 
P388 (Murine lymphocytic leukeamia), MCF7 (Human breast cancer), HepG2 
(Hepatocellular carcinoma) and J82 (Bladder transitional carcinoma) cancer cell lines. 
The IC50 values are given in Table 4. The hexane fraction showed very good activity 
against P388 cancer cell lines with IC50 value <10 μg/mL, the lowest concentration tested 
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and good activity against HL60 with IC50 value of 17.8 μg/mL but was inactive against 
all other cell lines screened; the IC50 values were 62.4, 72.0, 80.6 and >100 μg/mL, 
respectively against LL2, MCF7, HepG2 and J82 cancer cell lines. Owing to the 
promising activity of the hexane extract against P388 and HL60 cancer cell lines, we 
repeated the experiments with 12 kg of plant materials. This time the hexane fraction was 
not screened again for its cytotoxicity but chromatographed over a silica gel column 
using hexane and eluted with solvents of increasing polarity. Five major sub-fractions, 
(A-E), three minor fractions and one more fraction (A1) of about 90 % purity were 
obtained. The five major fractions (A-E) were screened against the above mentioned 
cancer cell lines and the results are given in Table 4. 
 
Fraction A showed no promising activity against all the cancer cell lines tested. It was not 
active even at a concentration of 100 μg/mL against HepG2, MCF7 and LL2 cancer cell 
lines and the IC50 values were 60.8, 72.0 and 80.8 μg/mL respectively, against P388, 
HL60 and J82 cancer cell lines. Fraction B showed weak activity against P388 with IC50 
value of 40.8 μg/mL and was inactive against all other cancer cell lines tested with IC50 
values of 65.6, 74.3, 64.8, 91.2, and > 100 μg/mL, respectively against MCF7, HepG2, 
J82, HL60 and LL2 cancer cell lines. Fraction C showed very good activity against LL2 
with IC50 value < 10 μg/mL, the lowest concentration tested and good activity against 
P388 and HL60 with IC50 values of 16.2 and 18.6 μg /mL, respectively. But it was 
inactive against three other cell lines with the IC50 values of 82.1, 63.6 and 64.8 μg/mL, 
respectively against J82, HepG2 and MCF7 cancer cell lines. Fraction D showed no 
activity against all the cell lines tested but the IC50 values were 40.8, 50.2 and 52.3 μg/ 
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mL, respectively against MCF7, P388 and HepG2 cancer cell lines; the IC50 value was 
>75 μg/mL against both HL60 and LL2, while it was >100 μg/mL against J82 cancer cell 
lines. Fraction E showed good activity against LL2 with IC50 value of 9.4 μg/mL and 
moderate activity against P388 with IC50 value 27.6 μg/mL; the IC50 values were 63.6, 
70.5 and 92.6 μg/mL respectively against HL60, HepG2 and MCF7 cancer cell lines; 
while it was >100 μg/mL against J82 cancer cell lines. 
 
Although Fraction A showed no activity against all the cancer cell lines tested, 
purification of this fraction led to isolation of a new triterpenoid compound of the 
cycloartane-type, 24(E)-ethylidenecycloartanone (93). Purification of Fractions B, C and 
D gave the known compounds friedelin (94), 3β-friedelinol (66) and β-sitosterol (47), 
respectively. Fraction E gave cycloartane-3,24-dione (95), a rarely encountered 
compound. Fraction (A1), obtained in about 90 % purity, was not screened for its 
cytotoxicity and on recrystalisation with acetone yielded the pure compound, 24(E)- 
ethylidenecycloartanone (93). The minor fractions were also not screened for their 
cytotoxicity due to their small quantities but preparative TLC led to isolation of the 
known compounds, β-sitosterol (47) and γ-sitosterol (96) and again the new compound 













                            (47)                                                             (66) 
 
Cycloartane-3,24-dione (95) was not screened for its cytotoxicity since it was isolated in 
a small quantity. The known compounds friedelin (94), 3β-friedelinol (66), β-sitosterol 
(47) and γ-sitosterol (96) were also not tested for their cytotoxicity since these 
compounds are very common natural products and there have been several reports citing 
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their cytotoxicity in the literature. Of the isolated pure compounds, only the new 
compound, 24(E)-ethylidenecycloartanone (93), was screened for its cytotoxicity against 
P388, HL60, LL2 and WEHI164 cancer cell lines and the results are given in Table 5. 
 
The chloroform fraction (obtained from 600g of plant material) was screened against the 
above mentioned cancer cell lines. It showed very good activity against both P388 and 
HL60 cancer cell lines with IC50 value < 10 μg/mL, the lowest concentration tested, but 
was inactive against all other cancer cell lines tested.  It showed the IC50 values of 52.3, 
66.6 and 78.2 μg/mL, respectively, against LL2, MCF7 and HepG2 cancer cell lines; 
while it was > 100 μg/mL against J82 cancer cell lines. This chloroform fraction 
(obtained from 600g plant material) was chromatographed over silica gel using hexane 
and eluted with solvents of increasing polarity. Further purification of a major fraction by 
HPLC (hexane/chloroform, 1:9) followed by preparative TLC (chloroform/methanol, 9:1) 
afforded 24-methylenecycloartanone (97) (7 mg) [107,108]. 
 
The chloroform fraction obtained from the second batch of plant material (12 kg), was 
not screened again for its cytotoxicity, but was chromatographed. Three major fractions F, 
G and H and four minor fractions were obtained. The major fractions, F-H were screened 
for their cytotoxicity against the above mentioned cancer cell lines. Fraction F showed no 
activity against MCF7, HepG2, P388, J82, HL60 and LL2 cancer cell lines. The IC50 
value was found to be >100 μg/mL on both MCF7 and HepG2 cancer cell lines; while it 
was 65.4, 70.4, 76.0 and 90.8 μg/mL, respectively against P388, J82, HL60 and LL2 
cancer cell lines. Fraction G showed very good activity against LL2 with IC50 value < 10 
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μg/mL and good activity against HL60 with IC50 value of 19.4 μg/mL, but was inactive 
against all other cell lines; the IC50 values were 51.8 and 90.4 μg/mL against P388 and 
HepG2 cancer cell lines and it was > 100 μg/mL against both MCF7 and J82 cancer cell 
lines. Fraction H showed borderline activity against MCF7 with IC50 value of 35.8 μg/mL 
but was inactive against all other cancer cell lines tested; the IC50 values were 65.4, 70.0, 
80.2, 80.8 and 92.0 μg/mL, respectively against P388, LL2, HepG2, HL60 and J82 
cancer cell lines. The minor fractions were not screened for their cytotoxicity since they 
were obtained in small quantities.  
 
The new compound, 24(E)-ethylidenecycloartanone (93), was isolated from Fraction F 
which was already isolated from the hexane sub-fractions. Another new compound, 
24(E)-ethylidenecycloartan-3α-ol (98) was isolated from Fraction G. It was already 
discussed that Fraction G, showed promising activity against LL2 and HL60 cancer cell 
lines with IC50 values of <10 μg/mL and 19.4 μg/mL, respectively. However, this 
compound (98) was not tested for cytotoxicity since it was obtained in small quantity. A 
known compound, β-sitosterol (47) was isolated from Fraction H. The known compound, 
β-sitosterol (47) and 24(E)-ethylidenecycloartanone (93) were again isolated from two 
minor fractions, one compound from each fraction. From the two other minor fractions, a 
new compound, 24,31-epoxy-24-ethylcycloartan-3α-ol (99) and the known compound β-
sitosterone (100), were isolated, one compound from each fraction. These compounds 








                                (98)                                                         (99) 
O HO  
                              (100)                                                        (47) 
Although 3β-friedelinol (66) was isolated from the active fraction C, our literature search 
revealed that it was not only inactive against P388 but also A549, MCF7, HT29 and KB 
cancer cell lines [109]. Friedelin (94) also showed no activity against P388, A549, MCF7, 
HT29 and KB cancer cell lines [109]. It was reported that friedelin (94) was cytotoxic 
against PC3 and U251 cancer cell lines [110]. At a concentration of 31μM, the 
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percentage of inhibition caused by friedelin, were 61.9, 25.8 and zero, respectively on 
PC3, U251 and K562 cancer cell lines [110]. Friedelin (94) is inactive against MCF7 
(breast cancer), TK10 (renal) UACC62 (melanoma), NCI-H460 (lung cancer) and SF-268 
(CNS) cancer cell lines [111].  
 
β-Sitosterol (47) is the major phytosterol in higher plants, including fruits and vegetables.  
This compound has shown potential for prevention and therapy for human cancer. β-
Sitosterol (47) treatment resulted in the inhibition of HCT116 human colon cancer cell 
proliferation in a concentration-dependent manner [112]. Breast cancer cell growth was 
inhibited by 66% after 3 days and by 80% after 5 days with 16 μM β-sitosterol. 
Supplementation of β-sitosterol (47) for 3 days at 16 μM resulted increase in apoptosis in 
cells. It was reported that β-sitosterol (47), by a still-unknown mechanism, protects from 
breast cancer by inhibiting growth and stimulating apoptosis [113-115]. This compound 
effectively inhibits invasion of tumour cells and metastasis [116]. β-Sitosterol (47)-
treated premalignant and malignant cells, accumulated in the G0/G1 and G2/M phases, 
respectively [117]. β-Sitosterol (47) exhibits a growth suppressing effect against two 
human cancer cell lines, MCF7 and BT20 [118,119]. β-Sitosterol (47) caused a high 
degree of growth inhibition on Hep-2 and McCoy cells [120]. It showed cytotoxic 
activity against human nasopharynx epidermoid cells [121].  
 
The methanol-water fraction was not tested for its cytotoxicity. However, purification of 
one of the eluted fractions afforded β-sitosterol (47).  
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2.2.2 Characterization of the isolated pure compounds from P. bistorta 
Our investigations on the chemical constituents of this plant, revealed the presence of a 
three new and two known cycloartane-type triterpenoids, as mentioned earlier. Other 
known compounds, β-sitosterol (47), friedelin (94), γ-sitosterol (96), 3β-friedelinol (66) 
and β-sitosterone (100) were also isolated. All the cycloartane-type compounds, friedelin 
(94) and β-sitosterone (100) were reported for the first time from this plant. The 
characterisation and/or identification of all these compounds are discussed below. 
 
24(E)-Ethylidenecycloartanone (93) 
The molecular formula for the compound, 24(E)-ethylidenecycloartanone (93) was 
deduced as C32H52O by the molecular ion peak at m/z 452.4019 in the HREIMS and 13C 
NMR analysis. The IR spectrum showed absorption peak for ketone functionality (νmax 
1712 cm-1). Inspection of its 13C and HSQC-DEPT spectra, revealed the presence 32 
signals; eight methyl, eleven methylene, six methine and seven quaternary carbons. The 
1H NMR spectrum of the compound revealed the presence of a cycloartane type skeleton 
with typical high-field AB doublets due to the non-equivalent hydrogens [δ 0.80 (d, J = 
4.5 Hz, Hα) and 0.59 (d, J = 4.3 Hz, Hβ)] at C-19 in the cyclopropane ring [122]. The 
presence of a cycloartane skeleton was supported by a fragmentation peak at m/z 313 (M- 
C10H19) in the MS, which was due to loss of the side chain [123]. The major MS 
fragmentation pattern of compound (93) is given in Scheme 1.  
 
The 1H-1H COSY spectrum together with HMQC data revealed that the compound (93) 
has seven distinct 1H-1H spin systems: (a) [-CH2-CH2-], (b) [>CH-CH2-CH2-CH<], (c)  
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[-CH2-CH2-], (d) [-CH2-CH2-CH<], (e) [-CH (CH3)-CH2-CH2-], (f) [CH3-CH-] and  
(g) [-CH-(CH3)2]. The 1H-1H spin system (a) [-CH2-CH2-] was assigned for C1 and C-2; 
since in the HMBC spectrum, C-1 showed correlation with H-2 and C-2 showed 
correlation with H-1. H-1 protons resonated at δ 1.87 (ddd, J = 13.8, 4.4, 1.5 Hz, Hα) and 
δ 1.56 (ddd, J = 13.5, 6.4, 2.7 Hz, Hβ). Similarly, H-2 protons resonated at δ 2.72 (ddd, J 
= 13.8, 4.4, 2.7 Hz, Hα) and δ 2.32 (ddd, J = 13.5, 6.4, 4.5Hz, Hβ). The multiplicity, ddd, 
indicated that each proton showed 3J couplings with vicinal protons (both Hα and Hβ) as 
well as 2J coupling with a geminal proton. The large coupling constant value, J >13 Hz 
was due to 3J trans coupling of each proton with its vicinal protons. The C-3 (δ 216.4) 
showed correlations with methyl protons at H-28 and H-29; similarly C-4 also showed 
correlations with methyl protons at H-28 and H-29. These correlations as well as the 
chemical shift value of δ 216.4 (C-3) allowed us to place the carbonyl carbon at C-3 
position and the attachment two methyl groups (C-28 and C-29) to the same carbon at C-
4. The H-1 and H-11 protons showed correlation with carbon at C-19 (δ 29.4) and C-5 
showed correlation with H-19. These correlations allowed us to place a methylene group 
(belongs to the cyclopropane ring) between C-9 and C-10. Further, H-19 protons are 
resonated at δ 0.80 (d, J = 4.5 Hz, Hα,) and 0.59 (d, J = 4.3 Hz, Hβ)]; they are non-
equivalent and each proton split in to a doublets due to 2J geminal couplings with each 
other. The spin system (b) [>CH-CH2-CH2-CH<] was assigned for the positions C-5 to 
C-8. C-5 showed correlation with H-19 and C-6 showed correlation with H-5. The single 
proton H-5 resonated at δ 1.73 (dd, J = 12.5, 4.5 Hz); the multiplicity, dd and the 
coupling constant values, J = 12.5 and 4.5 Hz were respectively, due the 3J trans and cis 
couplings with H-6 protons. Similarly, C-7 showed correlation with H-6 and C-8 showed 
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correlation with H-30. H-8 resonated at δ1.61 (dd, J = 12.5, 4.9 Hz) and the multiplicity, 
dd and the coupling constant values were due to 3J vicinal couplings with H-7 protons. 
All these correlations are in good agreement with the above spin system. The spin system 
(c) [-CH2-CH2-] was assigned for the positions C-11 and C-12; since C-11 showed 
correlations with H-8 and H-9 and C-12 showed correlation with H-18. The spin system 
(d) [-CH2-CH2-CH<] was assigned for positions C-15 to C-17. C-15 showed correlations 
with H-16 and H-30. C-17 showed correlation with H-21. Each proton in this spin system 
i.e. H-15, H-16 and H-17, exhibited a multiplet due to an availablity of several protons 
for both 3J and 2J couplings. The spin system (e) [-CH (CH3)-CH2-CH2-] was assigned 
for the positions C-20 to C-23. C-20 showed correlation with methyl protons at H-21 and 
this methyl protons (δ 0.92, d, J = 6.5 Hz) split in to a doublets due to 3J coupling with H-
20. C-21 showed correlation with H-17 and C-22 showed correlation with H-21. The spin 
system (f) [CH3-CH-] was assigned for an ethylidene moiety at C-24. C-31 showed 
correlations with H-23, H-25 and H-32. Similarly, C-32 showed correlation with H-31. 
Further, C-24 (δ 145.8) showed correlations with H-31 and H-32. In the 1D proton NMR 
spectrum, the protons on methyl group at C-32 gave a clearly defined doublets at δ1.60 (d, 
J = 6.0 Hz), due to 3J coupling with H-32, expected for an ethylidene group. The single 
proton on C-31 was also clearly evident showing the expected quartet at δ 5.13 (q, J = 6.5 
Hz). All these correlations supported the presence of an ethylidene moiety at C-24. 
Finally, the spin system (g) [-CH-(CH3)2] was assigned for an isopropyl moiety at C-24. 
In the HMBC spectrum, C-25 showed correlations with H-26 and H-27 and C-24 showed 
correlations with H-25, H-26 and H-27. The methyl protons at H-26 and H-27, each split 
in to a doublets due to 3J coupling with H-25. All these correlations indicated the 
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presence of an isopropyl moiety also at C-24. Other significant HMBC and 1H-1H COSY 





















            
                               (93)                                                              (101) 
Both 24(E)-ethylidenecycloartanone (93) and fucosterol (101) have an identical side 
chain structure. The 1H NMR chemical shift values for the latter compound at H-32 and 
H-31 were δ1.57 and 5.17, respectively [124]. Such a correlation also supported the 
proposed structure as well as used to assign the stereochemistry of 24(E)-ethylidene- 
cycloartanone (93) at C-24, which is similar to that of fucosterol (101). In other words, 











































   
 δC  
(ppm) 
 
δH (ppm)  
 J in Hz 
 
HMBC 





1 CH2 33.3 α: 1.87 ddd 
 (13.8, 4.4, 1.5) 
β: 1.56 ddd                       




2 CH2 37.4 α: 2.72 ddd 
 (13.5, 4.4, 2.7) 
β: 2.32 ddd  




3 C 216.4  2, 28, 29  
4 C 50.2  28, 29  
5 CH 48.4 1.73 dd (12.5, 4.5) 19 6 
6 CH2 21.5 α: 1.57 m; β : 0.96 m 5 5, 7 
7 CH2 25.8 α: 1.39 m;  β : 1.16 m 6 6, 8 
8 CH 47.8 1.61 dd (12.5, 4.9) 30 7 
9 C 21.0  1  
10 C 25.9  6  
11 CH2 26.7 α: 2.06 m; β: 1.19 m 8, 9 12 
12 CH2 32.7 1.68 m 18 11 
13 C 45.3  8, 18  
14 C 48.7  18  
15 CH2 35.5  1.33 m  16, 30 16 
16 CH2 28.1 α: 1.95 m;  β: 1.33 m  15, 17 
17 CH 52.2 1.63 m 21 16, 20  
18 CH3 18.0 1.01 s 12, 17  
19 CH2 29.4 α: 0.80 d (4.5) 
β: 0.59 d (4.3) 
1, 11   
20 CH 36.4 1.41 m 21 17, 22 
21 CH3 18.3 0.92 d (6.5) 17 20 
22 CH2 36.2 α: 1.55 m;  β: 1.12 m 21 23 
23 CH2 28.2 α: 2.03 m;  β: 1.78 m  22 
24 C 145.8  23, 25, 26, 
27, 31, 32  
 
25 CH 28.5 2.84 m 26, 27 26, 27 
26 CH3 21.0 1.00 d (6.4) 25, 27 25 
27 CH3 21.0 1.00 d (6.4) 25, 26 25 
28 CH3 22.1 1.06 s 5, 29  
29 CH3 20.7 1.11 s 5, 28  
30 CH3 19.2 1.79 s 8, 15  
31 CH 116.4 5.13 q (6.5) 23, 25, 32 32 





24(E)-Ethylidenecycloartan-3α-ol (98) was obtained as colourless crystals. It gave a 
molecular ion peak at m/z 454.4175 in the HREIMS, corresponding to the molecular 
formula C32H54O. Inspection of its 13C and HSQC-DEPT spectra, revealed the presence 
32 signals; eight methyl, eleven methylene, seven methine and six quaternary carbons. 
The 1H NMR spectrum indicated the presence of cycloartane-type skeleton with typical 
high-field AB doublets due to the non-equivalent hydrogens [δ 0.49 (d, J = 4.0 Hz, Hα) 
and 0.33 (d, J = 4.0 Hz, Hβ)] at C-19 in the cyclopropane ring (Table 7). In the MS 
spectrum, a fragment peak at m/z 315 (M- C10H19) was observed, which was an indicative 
of the presence of a cycloartane skeleton with hydroxyl group in the nucleus and C10 side 
chain. Most of our spectral correlations were similar to 24E-ethylidenecycloartanone (93) 
but a mass unit difference of 2 amu was observed in the MS spectrum.  
 
The 1H-1H COSY spectrum together with HMQC data revealed that the compound (98) 
has seven distinct 1H-1H spin systems: (a) [-CH2-CH2-CH(O)], (b) [>CH-CH2-CH2-CH<], 
(c) [-CH2-CH2-], (d) [-CH2-CH2-CH<], (e) [-CH-(CH3)-CH2-CH2-], (f) [CH3-CH-] and  
(g) [-CH-(CH3)2]. The 1H-1H spin system (a) [-CH2-CH2-CH (O)-] was assigned for C1, 
C-2 and C-3. In the HMBC spectrum, C-1 showed correlation with H-2; C-2 showed 
correlation with H-1 and C-3 (δ 77.0) showed correlations with H-2, H-28 and H-29. 
Thus, the oxymethine proton was placed in this spin system at C-3. Similarly, C-4 also 
showed correlations with methyl protons at H-28 and H-29. These correlations allowed 
us to place the two methyl groups (C-28 and C-29) to the same carbon at C-4. The H-1 
and H-11 protons showed correlation with carbon at C-19 (δ 29.7) and C-5 showed 
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correlation with H-19. These correlations allowed us to place a methylene group (belongs 
to the cyclopropane ring) between C-9 and C-10. Further, H-19 protons are resonated at δ 
0.49 (d, J = 4.0 Hz, Hα,) and 0.33 (d, J = 4.0 Hz, Hβ)]; they are non-equivalent and each 
proton split in to doublets due to 2J geminal couplings with each other. The spin system 
(b) [>CH-CH2-CH2-CH<] was assigned for the positions C-5 to C-8. C-5 showed 
correlation with H-19 and C-6 showed correlation with H-5. Similarly, C-7 showed 
correlation with H-6 and C-8 showed correlations with H-19 and H-30. H-8 resonated at 
δ1.50 (m) and this multiplet was due to 3J vicinal couplings with H-7 and 2J geminal 
coupling with H-8. All these correlations are in good agreement with the above spin 
system. The spin system (c) [-CH2-CH2-] was assigned for the positions C-11 and C-12; 
since C-11 showed correlations with H-8 and H-9 and C-12 showed correlation with H-
18. The spin system (d) [-CH2-CH2-CH<] was assigned for positions C-15 to C-17. C-17 
showed correlation with H-21. Each proton in this spin system i.e. H-15, H-16 and H-17, 
exhibited a multiplet due to an availablity of several protons for both 3J and 2J couplings. 
The spin system (e) [-CH-(CH3)-CH2-CH2-] was assigned for the positions C-20 to C-23. 
C-20 showed correlation with methyl protons at H-21 and this methyl protons (δ 0.92, d, 
J = 5.2 Hz) split in to a doublets due to 3J coupling with H-20. C-21 showed correlation 
with H-17 and C-22 showed correlation with H-21. The spin system (f) [CH3-CH-] was 
assigned for an ethylidene moiety at C-24. C-31 showed correlations with H-23, H-25 
and H-32. Similarly, C-32 showed correlation with H-31. Further, C-24 (δ 149.5) showed 
correlations with H-31 and H-32. In the 1D proton NMR spectrum, the protons on methyl 
group at C-32 gave a doublets at δ1.58 (d, J = 6.1 Hz), due to 3J coupling with H-32, 
expected for an ethylidene group. The single proton on C-31 was also clearly evident 
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showing the expected quartet at δ 5.17 (q, J = 6.7 Hz). All these correlations supported 
the presence of an ethylidene moiety at C-24. Finally, the spin system (g) [-CH-(CH3)2] 
was assigned for an isopropyl moiety at C-24. In the HMBC spectrum, C-25 showed 
correlations with H-26 and H-27 and C-24 showed correlations with H-23, H-25, H-26 
and H-27. The methyl protons at H-26 and H-27, each split in to a doublets due to 3J 
coupling with H-25. All these correlations indicated the presence of an isopropyl moiety 
also at C-24.  
HO
 
                                                                   (98) 
Overall, the HMBC and 1H-1H COSY spectral correlations of compound (98) were 
comparable to 24(E)-ethylidenecycloartanone (93), but in the 1H-1H COSY spectrum, H-3 
also showed correlation with H-2. The 1H and 13C chemical shift values at C-3 position 
were observed as δ 3.45 (br, s) and 77.0 respectively, indicated the presence of a 
hydroxyl functionality at C-3. Further, the stereochemical orientation of this hydroxyl 
functionality was observed as α, which was confirmed by comparing the above chemical 
shift values and multiplicity at this position with a related compound [125].  For a β-
orientation, these chemical shift values would be around δ 3.28 (m) and 78.8, respectively 
[126,127]. The spectral correlations regarding its side chain structure and NMR chemical 
shift values for other positions are also comparable to 24(E)-ethylidenecycloartanone (93). 
The 1H-1H COSY and significant HMBC correlations are listed in Table 7.  
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Table 7 







   
 δC  
(ppm) 
 
δH (ppm)  
 J in Hz 
 
HMBC 




1 CH2 27.5 α: 1.56 m; β: 1.24 m 2 2 
2 CH2 28.5 α: 2.72 m; β: 1.56 m 1 1, 3 
3 CH 77.0 3.45 br s 2, 28, 29 2 
4 C 39.5  28, 29  
5 CH 41.0 1.28 m 19 6 
6 CH2 21.1 α: 1.58 m; β: 0.80 m 5 5, 7 
7 CH2 28.2 α: 1.87 m; β: 1.28 m 6 6, 8 
8 CH 47.8 1.50 m  19, 30 7 
9 C 19.8  1  
10 C 26.4  6  
11 CH2 26.2 α: 1.96 m; β:1.10 m 8, 9 12 
12 CH2 32.8 1.68 m  18 11 
13 C 45.3  8, 18  
14 C 48.9  18  
15 CH2 35.4 1.28 m   16 
16 CH2 25.9 α: 1.33 m;  β: 1.10 m  15, 17 
17 CH 52.0 1.56 m 21 16, 20  
18 CH3 19.3 0.94 s 12, 17  
19 CH2 29.7 α: 0.49 d (4.0) 
β: 0.33 d (4.0) 
1, 11   
20 CH 35.9 1.36 m 21 17, 22 
21 CH3 18.1 0.92 d (5.2) 17 20 
22 CH2 34.7 α: 1.34 m; β: 0.92 m 21 23 
23 CH2 26.8 α: 1.33 m; β: 1.10 m  22 
24 C 149.5  23, 25, 26,  
27, 31, 32  
 
25 CH 29.5 2.80 m 26, 27 26, 27 
26 CH3 21.9 0.92 d (6.0) 25, 27 25 
27 CH3 21.9 0.81 d (6.0) 25, 26 25 
28 CH3 22.2 0.88 s 5, 29  
29 CH3 20.8 0.92 s 5, 28  
30 CH3 19.3 0.85 s 8, 15  
31 CH 116.4 5.17 q (6.7) 23, 25, 32 32 








24,31-Epoxy-24-ethylcycloartan-3α-ol (99) was obtained as colourless amorphous 
powder and gave a molecular ion peak 470.4123 in the HREIMS, corresponding to the 
molecular formula C32 H54 O2. Inspection of its 13C and HSQC-DEPT spectra, revealed 
the presence 32 signals; eight methyl, eleven methylene, seven methine and six 
quaternary carbons. The 1H NMR spectrum of compound indicated the presence of a 
cycloartane skeleton with typical high-field AB doublets due to non-equivalent protons at 
C-19 of the cyclopropane ring as reported in the other two new compounds, (93) and (98). 
The fragment ion at m/z 315(M-C10H19O) was also an evidence of the presence of a 





In the HMBC spectrum, C-1 showed correlation with H-2; C-2 showed correlation with 
H-1 and C-3 (δ 77.2) showed correlations with H-2, H-28 and H-29. Similarly, C-4 also 
showed correlations with methyl protons at H-28 and H-29. These correlations together 
with 13C NMR (δ 77.2) and 1H NMR (δ 3.50) chemical shift values, allowed us to place 
one of the oxymethine protons at C-3 and the two methyl groups (C-28 and C-29) to the 
same carbon at C-4. The H-1 and H-11 protons showed correlation with carbon at C-19 
(δ 29.7) and C-5 and C-8 showed correlation with H-19. These correlations allowed us to 
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place a methylene group (belongs to the cyclopropane ring) between C-9 and C-10. 
Further, H-19 protons are resonated at δ 0.51 (d, J = 4.2 Hz, Hα) and 0.36 (d, J = 4.2 Hz, 
Hβ); they are non-equivalent and each proton split in to a doublets due to 2J geminal 
coupling with each other. C-5 showed correlation with H-19 and C-6 showed correlation 
with H-5. Similarly, C-7 showed correlation with H-6 and C-8 showed correlations with 
H-19 and H-30. H-8 resonated at δ1.47 (m) and this multiplet was due to 3J vicinal 
coupling with H-7 and 2J geminal coupling with H-8. These correlations allowed us to 
form a skeleton of C-5 to C-8. C-15 showed correlations with H-16 and H-30. These 
correlations together with the correlation of C-8 with H-30 allowed us to place a methyl 
group (C-30) at C-14 position. Similarly, C-11 showed correlations with H-8 and H-9 and 
C-12 showed correlation with H-18. C-13 showed correlations with H-8 and H-18. C-14 
showed correlation with H-18. All these correlations allowed us to place another methyl 
group (C-18) at C-13 position. C-11 showed correlations with H-8 and H-9 and C-12 
showed correlation with H-18. These correlations allowed us to form a skeleton of C-11 
and C-12. C-15 showed correlations with H-16 and H-30 and C-17 showed correlation 
with H-21. These correlations allowed us to form a skeleton of C-15 to C-17. Further, 
each proton at H-15, H-16 and H-17 exhibited a multiplet due to an availablity of several 
protons for both 3J and 2J couplings. C-20 showed correlation with methyl protons at H-
21 and this methyl protons (δ 0.95, d, J = 5.0 Hz) split in to a doublets due to 3J coupling 
with H-20. C-21 showed correlation with H-17 and C-22 showed correlation with H-21. 
C-31 showed correlations with H-23, H-25 and H-32. Similarly, C-32 showed correlation 
with H-31. Further, C-24 (δ 149.5) showed correlations with H-31 and H-32. In the 1d 
proton NMR spectrum, the protons on methyl group at C-32 gave a doublets at δ1.58 (d, 
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J = 6.2 Hz), due to 3J coupling with H-32. The single proton on C-31 gave a quartet at δ 
2.87 (q, J = 6.5 Hz). All these correlations were indicated the presence of a [CH3-CH-] 
moiety at C-24. In the HMBC spectrum, C-25 showed correlations with H-26 and H-27 
and C-24 showed correlations with H-23, H-25, H-26 and H-27. The methyl protons at 
H-26 and H-27, each split in to a doublets due to 3J coupling with H-25. All these 
correlations indicated the presence of an isopropyl moiety also at C-24.  
 
Most of the spectral correlations have close similarity to 24(E)-ethylidenecycloartan-3α-
ol (98) including the stereochemistry at C-3 position. However, the 13C spectrum 
exhibited three oxygenated carbons, one of them was assigned to C-3 (δ 77.2) and two 
other were assigned to respectively, C-24 (δ 60.2) and C-31 (δ 65.2) (Table 8). Further, 
HSQC-DEPT spectrum revealed that C-24 and C-31 were respectively quaternary and 
methine carbons. Attaching hydroxyl group on both or any one of the carbons at C-24 or 
C-31 was ruled out, since doing so will cause the molecular weight to be exceeded than 
actual. Based on these observations, we placed the oxygen atom as an epoxy function 
between C-24 and C-31 positions, unambiguously. A fragment ion in the mass spectrum 
at m/z 454 (M-O) was a further evidence that one of the oxygen atoms was present in the 
form of epoxy function. The major fragment ions were depicted in Scheme 2. However, 










































































   
 δC  
(ppm) 
 
δH (ppm)  
 J in Hz 
 
HMBC 
(C → H) 
1 CH2 27.3 α: 1.57 m; β: 1.25 m 2 
2 CH2 28.4 α: 1.75 m; β: 1.56 m 1 
3 CH 77.2 3.50 br s 2, 28, 29 
4 C 39.7  28, 29 
5 CH 41.0 1.28 m  19 
6 CH2 21.2 α: 1.60 m; β: 0.83 m 5 
7 CH2 28.2 α: 1.89 m; β: 1.28 m 6 
8 CH 48.0 1.47 m  19, 30 
9 C 19.8  1 
10 C 26.4  6 
11 CH2 26.2 α: 1.90 m; β: 1.12 m 8, 9 
12 CH2 32.8 1.60 m  18 
13 C 45.5  8, 18 
14 C 49.2  18 
15 CH2 35.6 1.31 m  16, 30 
16 CH2 26.1 α: 1.27 m; β: 1.12 m  
17 CH 52.2 1.60 m 21 
18 CH3 19.5 0.98 s 12, 17 
19 CH2 29.7 α: 0.51 d (4.2)  
β: 0.36 d (4.2) 
1, 11  
20 CH 36.1 1.40 m 21 
21 CH3 18.3 0.95 d (5.0) 17 
22 CH2 34.8 α: 1.36 m;  β: 0.95 m 21 
23 CH2 26.8 α: 1.29 m;  β: 1.12 m  
24 C 65.2  23, 25, 26, 
27, 31, 32  
25 CH 29.8 2.82 m 26, 27 
26 CH3 21.9 0.95 d (5.9) 25, 27 
27 CH3 21.9 0.82 d (5.9) 25, 26 
28 CH3 22.4 0.90 s 5, 29 
29 CH3 20.8 0.92 s 5, 28 
30 CH3 19.5 0.84 s 8, 15 
31 CH 60.2 2.87 q (6.5) 23, 25, 32 
32 CH3 12.8 1.58 d (6.2) 31 
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Cycloartane-3,24-dione (95) 
Cycloartane-3,24-dione (95) was obtained as colourless crystals. It gave a molecular ion 
peak at m/z 440.3655 in the HREIMS, corresponding to the molecular formula C30H48O2. 
Inspection of its 13C and HSQC-DEPT spectra, revealed the presence 30 signals; seven 
methyl, eleven methylene, five methine and seven quaternary carbons. The 13C NMR 
chemical shift values of two carbons were observed at δ 215.4 and 216.5 respectively, 
assigned for two carbonyl groups.  No signals were observed for an olefinic bond or 
hydroxyl group. The 1H NMR spectrum indicated the presence of a methylene group in 
the form of cyclopropane ring (cycloartane-type) and the two non-equivalent hydrogens 
resonated at high-field region at δ 0.78 (d, J = 4.3 Hz, Hα) and 0.57 (d, J = 4.3 Hz, Hβ) 
respectively (Table 9). The fragment peak at m/z 313 (M- C8H15O) in the MS spectrum 
was supported the presence of a cycloartane skeleton; which also supported the presence 





In the HMBC spectrum, C-1 showed correlation with H-2 and H-19 and C-2 showed 
correlation with H-1. H-1 protons resonated at δ 1.85 (ddd, J = 13.5, 4.0, 1.4 Hz, Hα) and 
δ 1.56 (ddd, J = 13.5, 4.4, 2.7 Hz, Hβ). Similarly, H-2 protons resonated at δ 2.72 (ddd, J 
= 13.5, 4.4, 2.7 Hz, Hα) and δ 2.32 (ddd, J = 13.5, 6.5, 4.5 Hz, Hβ). The multiplicity, ddd, 
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indicated that each proton showed 3J couplings with vicinal protons (Hα and Hβ) as well 
as 2J coupling with a geminal proton. The C-3 (δ 216.4) carbon showed correlations with 
methyl protons at H-28 and H-29; similarly C-4 also showed correlations with methyl 
protons at H-28 and H-29. These correlations as well as the chemical shift value δ 216.4 
(C-3) allowed us to place the carbonyl carbon at C-3 position and the attachment two 
methyl groups (C-28 and C-29) to the same carbon at C-4. The H-1 and H-11 protons 
showed correlation with carbon at C-19 (δ 29.5) and C-5 showed correlation with H-19. 
These correlations allowed us to place a methylene group (belongs to the cyclopropane 
ring) between C-9 and C-10. Further, H-19 protons are resonated at δ 0.78 (d, J = 4.3 Hz, 
Hα,) and 0.57 (d, J = 4.3 Hz, Hβ); they are non-equivalent and each proton split in to a 
doublets due to 2J geminal coupling with each other. C-5 showed correlation with H-19 
and C-6 showed correlation with H-5. The single proton H-5 resonated at δ 1.70 (dd, J = 
12.5, 4.5 Hz); the multiplicity, dd and the coupling constant values J = 12.5 and 4.5 Hz 
were, respectively, due to 3J trans and cis couplings with H-6 protons. Similarly, C-7 
showed correlation with H-6 and C-8 showed correlation with H-30. H-6 protons are 
resonated at δ 1.37 (dddd, J = 12.5, 12.5, 12.5, 3.0 Hz, Hα,) and 1.12 (dddd, J = 12.5, 4.9, 
4.9, 2.5 Hz, Hβ); the multiplicity indicated that each proton showed 3J vicinal couplings 
with H-7 and H-5 and 2J geminal coupling with H-6. H-8 resonated at δ1.58 (dd, 12.5, 
4.9 Hz) and the multiplicity, dd and the coupling constant values were due to 3J vicinal 
couplings with H-7 protons. These correlations allowed us to form a skeleton of C-5 to C-
8. C-15 showed correlations with H-30. These correlations together with the correlation 
of C-8 with H-30 allowed us to place a methyl group (C-30) at C-14 position. Similarly, 
C-11 showed correlations with H-19 and C-12 showed correlation with H-18. C-13 
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showed correlation with H-18 and H-30. C-14 showed correlation with H-18 and H-30. 
All these correlations allowed us to place another methyl group (C-18) at C-13 position. 
C-11 showed correlations with H-9 and C-12 showed correlation with H-18. These 
correlations allowed us to form a skeleton of C-11 and C-12. C-15 showed correlations 
with H-30 and C-17 showed correlation with H-18 and H-21. These correlations allowed 
us to form a skeleton of C-15 to C-17. Further, each proton at H-15, H-16 and H-17 
exhibited a multiplet due to an availablity of several protons for both 3J and 2J couplings. 
C-20 showed correlation with methyl protons at H-21 and this methyl protons (δ 1.09, d, 
J = 6.5 Hz) split in to a doublets due to 3J coupling with H-20. H-17, H-20 and H-22 
showed correlation with methyl carbon at C-21. H-23, H-25, H-26 and H-27 showed 
correlations with C-24. The methyl protons at H-26 and H-27, each split in to a doublets 
due to 3J coupling with H-25. All these correlations indicated the presence of an 
isopropyl moiety also at C-24 (δ 215.4) and the attachment of two methyl groups (C-26 
and C-27) to the same carbon at C-25. In addition, the same correlations allowed us to 
place the second carbonyl groups at C-24 (δ 215.4). The McLafferty rearrangement 
product at m/z 354 supported the presence of a carbonyl group in the side chain at C-24. 
Other significant HMBC correlations are listed in Table 9.  
 
Although this compound had earlier been reported as an inseparable mixture, the 
identification was made based on only MS fragmentation pattern of GC-MS analysis 
[128].  However the same compound was isolated from another species and reported in a 
pure state [107] but it had inconsistency with our assignment, in particular at the C-3 
position. The MS fragmentation pattern obtained for cycloartane-3,24-dione (95) was 
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identical as reported in the literature [107]. NMR assignments were made for this 
compound and are listed in Table 9. 
 
Table 9  










δH (ppm)   
J in Hz 
 
HMBC 
(C → H) 
1 CH2 33.3 α: 1.85 ddd (13.5, 4.0, 1.4) 
β: 1.56 ddd (13.5, 4.4, 2.7) 
2, 19 
2 CH2 37.4 α: 2.72 ddd (13.5, 4.4, 2.7) 
β: 2.32 ddd (13.5, 6.5, 4.5) 
1 
3 C 216.4  2, 28, 29 
4 C 50.2  28, 29 
5 CH 48.4 1.70 dd (12.5, 4.5) 19 
6 CH2 21.5 α: 1.37 dddd (12.5, 12.5, 12.5, 3.0) 
β: 1.12 dddd (12.5, 4.9, 4.9, 2.5) 
5 
7 CH2 25.8 α: 1.39 m;  β: 1.16 m 6 
8 CH 47.9 1.58 dd (12.5, 4.9) 30 
9 C 21.0  8, 11 
10 C 25.9  5, 19 
11 CH2 26.7 α: 2.05 m; β: 1.16 m 19 
12 CH2 32.8 1.64 m 18 
13 C 45.3  18, 30 
14 C 48.7  18, 30 
15 CH2 35.5 1.32 m 30 
16 CH2 28.0 α: 1.94 m;  β: 1.32 m  
17 CH 52.2 1.59 m 18, 21 
18 CH3 18.3 1.09 s  
19 CH2 29.5 α: 0.78 d (4.3);  β: 0.57 d (4.3) 1, 11 
20 CH 35.6 1.39 m 21 
21 CH3 20.8 1.09 d (6.5)  
22 CH2 30.0 α: 1.77 m;  β: 1.24 m 21 
23 CH2 37.4 α: 2.14 ddd (16.6 ,9.7, 6.0 )  
β: 2.14 ddd (16.6, 10.0, 5.2)  
 
24 C 215.4  23, 25, 
26, 27, 
25 CH 40.8 2.61 m 26, 27 
26 CH3 18.6 0.86 d (6.4) 25, 27 
27 CH3 18.0 0.98 d (6.4) 25, 26 
28 CH3 22.1 1.04 s 5, 29 
29 CH3 20.7 1.09 s 5, 28 





24-Methylenecycloartanone (97) was obtained as colourless crystals. The molecular 
formula of the compound was deduced as C31H50O by the molecular ion peak at m/z 438 
in the EIMS and 13C NMR analysis. The IR spectrum of this compound showed 
absorption for ketone functionality (νmax 1712 cm-1). Inspection of its 13C and HSQC-
DEPT spectra, revealed the presence 31 signals; seven methyl, twelve methylene, five 
methine and seven quaternary carbons. There was one carbonyl carbon (δ 216.5) and one 
double bond (δ156.9 and 105.9) as revealed from its 13C NMR chemical shift values. The 
1H NMR spectrum of the compound revealed the presence of cycloartane-type skeleton 
with typical high-field AB doublets due to the non-equivalent hydrogens at δ 0.52 (d, J = 
4.2 Hz, Hα) and 0.35 (d, J = 4.2 Hz, Hβ) at C-19 in the cyclopropane ring [122]. The 
fragment peak at m/z 313 (M-C10H19O) in the MS spectrum was also supported the 
presence of a cycloartane skeleton with a carbonyl group in the nucleus and C9 side chain.   
O
                                                                
(97) 
In the HMBC spectrum, C-1 showed correlation with H-2 and C-2 showed correlation 
with H-1. H-1 protons resonated at δ 1.88 (ddd, J = 13.5, 4.0, 1.4 Hz, Hα) and 1.04 (m, 
Hβ). Similarly, H-2 protons resonated at δ 2.72 m, Hα and 1.96 (ddd, J = 13.5, 6.5, 4.5 
Hz, Hβ). The multiplicity indicated that each proton showed 3J couplings with vicinal 
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protons (Hα and Hβ) as well as 2J coupling with a geminal proton. The C-3 (δ 216.4) 
carbon showed correlations with methyl protons at H-28 and H-29; similarly C-4 also 
showed correlations with methyl protons at H-28 and H-29. These correlations as well as 
the chemical shift value δ 216.5 (C-3) allowed us to place the carbonyl carbon at C-3 
position and the attachment two methyl groups (C-28 and C-29) to the same carbon at C-
4. The H-1 and H-11 protons showed correlation with carbon at C-19 (δ 29.8) and C-5 
showed correlation with H-19. These correlations allowed us to place a methylene group 
(belongs to the cyclopropane ring) between C-9 and C-10. Further, H-19 protons are 
resonated at δ 0.52 (d, J = 4.2 Hz, Hα,) and 0.35 (d, J = 4.2 Hz, Hβ); they are non-
equivalent and each proton split in to a doublets due to 2J geminal coupling with each 
other. C-5 showed correlation with H-19 and C-6 showed correlation with H-5. The 
single proton H-5 resonated at δ 1.85 (dd, J = 12.6, 4.5 Hz); the multiplicity, dd and the 
coupling constant values J = 12.5 and 4.5 Hz were, respectively, due to 3J trans and cis 
couplings with H-6 protons. Similarly, C-7 showed correlation with H-6 and C-8 showed 
correlations with H-19 and H-30. H-6 protons are resonated at δ 1.51 (dddd, J = 12.6, 4.6, 
4.5, 2.7 Hz, Hα,) and 0.79 (dddd, J = 12.6, 12.6, 12.6, 2.5 Hz, Hβ); the multiplicity 
indicated that each proton showed 3J vicinal couplings with H-7 and H-5 and 2J geminal 
coupling with H-6 proton. Similarly, H-7 protons are resonated at δ 1.15 (dddd, J = 12.6, 
12.6, 12.7, 2.5 Hz, Hα,) and 1.33 (dddd, J = 12.6, 4.6, 4.6, 2.6 Hz, Hβ); the multiplicity 
indicated that each proton showed 3J vicinal couplings with H-6 and H-8 and 2J geminal 
coupling with H-7 proton. H-8 resonated at δ1.56 (dd, 12.6, 4.6 Hz) and the multiplicity, 
dd and the coupling constant values were due to 3J vicinal couplings with H-7 protons. 
These correlations allowed us to form a skeleton of C-5 to C-8. C-15 showed correlations 
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with H-30. These correlations together with the correlation of C-8 with H-30 allowed us 
to place a methyl group (C-30) at C-14 position. Similarly, C-11 showed correlations 
with H-19 and C-12 showed correlation with H-18. C-13 showed correlation with H-18 
and H-30. C-14 showed correlation with H-18. All these correlations allowed us to place 
another methyl group (C-18) at C-13 position. C-11 showed correlations with H-8 and H-
9 and the H-11 protons resonated at δ 2.03 (ddd, J = 15.0, 8.0, 7.5 Hz, Hα) and δ 1.16 
(ddd, J = 15.0, 7.5, 6.0 Hz, Hβ). The multiplicity indicated that each proton showed 3J 
couplings with vicinal protons (Hα and Hβ) at H-12 as well as 2J coupling with a geminal 
proton at H-11. C-12 showed correlation with H-18. These correlations allowed us to 
form a skeleton of C-11 and C-12. Further, each proton at H-15, H-16 and H-17 exhibited 
a multiplet due to an availablity of several protons for both 3J and 2J couplings. C-20 
showed correlation with methyl protons at H-21 and this methyl protons δ 0.90 (d, J = 7.0 
Hz) split in to a doublets due to 3J coupling with H-20. The protons at H-17, H-20 and H-
22 showed correlation with methyl carbon at C-21. H-23, H-25, H-26 and H-27 showed 
correlations with C-24. H-17 showed correlation with methyl carbon at C-21. H-25, H-26 
and H-27 showed correlations with C-24; H-26 and H-27 showed correlations with C-25. 
Similarly, C-31 showed correlation with H-25. All these correlations allowed us to place 
C-31 methylene group at C-24 (δ 156.9) and the attachment of two methyl groups (C-26 
and C-27) to the same carbonyl at C-25. The methylene protons at C-31 were non-
equivalent and also olefinic. Since, they exhibited 1H NMR chemical shift values at δ 
4.66 (1H, d, J = 1.5 Hz) and 4.71 (1H, br, s). The placement of double bond between C-
24 and C-31 was also supported by the 13C NMR chemical shift values of C-31 (δ 105.9) 
and C-24 (δ 156.9). Compound (97) is a very common cycloartane triterpenoid and has 
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been reported several times from other species. Comparison of spectral data with those 
reported previously had good agreement with our data [107,108]. Other significant 
HMBC correlations are listed in Table 10. 
Table 10 








  δC 
(ppm) 
 
     δH (ppm)  
       J in Hz 
 
HMBC 
(C → H) 
1 CH2 27.5 α: 1.88 ddd (13.8, 13.8, 2.7) 
β: 1.04 m 
2 
2 CH2 28.6 α: 1.66 m 
β: 1.96 ddd (13.8, 13.8, 4.0) 
1 
3 C 216.5  2, 28, 29 
4 C 39.6  28, 29 
5 CH 41.1 1.85 dd (12.6, 4.5) 19 
6 CH2 21.1 α: 1.51 dddd (12.6, 4.6, 4.5, 2.7) 
β: 0.79 dddd (12.6, 12.6, 2.5, 12.6) 
5 
7 CH2 25.7 α: 1.15 dddd (12.6, 12.6, 2.5, 12.7) 
β: 1.33 dddd (12.6, 2.6, 4.6, 4.6) 
6 
8 CH 48.0 1.56 dd (12.6, 4.6) 19, 30 
9 C 19.8  1 
10 C 26.4  6 
11 CH2 26.2 α: 2.03 ddd (15.0, 8.0, 7.5) 
β: 1.16 ddd (15.0, 7.5, 6.0) 
8, 9 
12 CH2 32.8 1.65 m 18 
13 C 45.3  8, 18 
14 C 48.9  18 
15 CH2 35.5 1.32 m   
16 CH2 28.2 α: 1.94 m;  β: 1.32 m  
17 CH 52.3 1.64 m 21 
18 CH3 18.0 0.97 s 12, 17 
19 CH2 29.8 α: 0.52 d (4.2);  β: 0.35 d (4.2) 11 
20 CH 36.2 1.42 m 21 
21 CH3 18.3 0.90 d (7.0) 17 
22 CH2 35.0 α: 1.19 m;  β: 1.60 m 21 
23 CH2 31.3 α: 1.19 m;  β: 2.15 m 31 
24 C 156.9  25, 26, 27  
25 CH 33.8 2.26 m 26, 27 
26 CH3 21.9 1.03 d (6.8) 25, 27 
27 CH3 22.0 1.03 d (6.8) 25, 26 
28 CH3 25.9 0.95 s 5, 29 
29 CH3 21.2 0.88 s 5, 28 
30 CH3 19.3 0.91 s 8, 15 




β-Sitosterol (47) was obtained as colourless flakes. The IR spectrum demonstrated the 
presence of hydroxyl group (νmax 3429 cm-1) and double bond (νmax 1662 cm-1) functions 
in the molecule. The mass spectrum of the compound showed a molecular ion peak at m/z 
414 and a peak at m/z 396 (M-18) due to loss of a water molecule.  
HO  
(47) 
A characteristic signal at 5.36 (br d, J = 5.4 Hz) indicated the presence of an olefinic 
proton and a peak at δ 3.52 (m, 1H) showed the presence of a hydroxyl group. The 13C 
NMR spectrum gave 29 signals; six methyl, eleven methylene, nine methine and three 
quaternary carbons were sorted by HSQC-DEPT spectrum. The 13C NMR spectrum 
showed peaks at δ 71.8 and 140.8 & 121.7 that confirmed the presence of a hydroxyl and 
olefinic carbons, respectively. Melting point range was found to be 136.1-138.0 ˚C which 
had good agreement with reported literature value [129,130]. With all these information, 
the compound was confirmed as β-sitosterol (47). Comparison of the spectral data with 
those reported in the literature also had good agreement [131,132].  
γ-Sitosterol (96) 
γ-Sitosterol (96) was obtained as colourless crystals. Most of the spectral correlations are 
identical to β-sitosterol (47). The only difference between this compound and β-sitosterol 
(47) is the stereochemistry at C-24.  
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HO  
                                                             (96) 
However this compound can easily be distinguished from β-sitosterol (47) by its melting 
point, 147-148 ˚C [133,134] and relative intensity of the molecular ion and fragment 
peaks in the MS. The melting point difference between compounds, β-sitosterol (47) and 
γ-sitosterol (96) is ~ 10 ˚C. 
 
β-Sitosterone (100) 
β-Sitosterone (100) was obtained as an amorphous powder. It gave a molecular ion peak 
at m/z 412 and other fragment peaks at m/z 397, 370, 289, 229,149, 124, 55 and 43. The 
fragmentation peak at m/z 124 indicates the presence of a keto group in the ring.  
O  
                                                          (100) 
It gave a peak at δ 5.7 (1H, s) was characteristic for an olefinic proton. Its spectral data 




3β-Friedelinol (66) was obtained as colourless crystals. The IR spectrum revealed the 
presence of hydroxyl functionality in the molecule (νmax 3500 cm-1). The mass spectrum 
gave a molecular ion peak at m/z 428. The 13C NMR spectrum gave 30 signals; eight 
methyl, eleven methylene, five methine and six quaternary carbons were sorted by 
HSQC-DEPT spectrum. One of the carbons resonated at δ 72.8 and indicated the 
presence of a hydroxyl group. The 1H NMR spectrum gave a peak at δ 3.73 which 





















In the HMBC spectrum, C-1 showed correlations with H-3 and H-10. H-3 resonated at 
3.73 (q-like, J = 9.5, 3.0 Hz); the HMBC correlations and this chemical shift value 
allowed us to place the hydroxyl functionality at this position (C-3). H-10 resonated at δ 
0.86 (dd, J = 12.0, 2.0 Hz); the multiplicity, dd, was due to a coupling of this proton with 
H-1 protons. C-3 (δ 72.8) showed correlations with H-2 and H-23. These correlations and 
the chemical shift value supported to place the hydroxyl functionality at C-3 and a methyl 
group (C-23) at C-4.  Further, in the 1D proton NMR spectrum, the methyl group at C-23 
split in to a doublets, which was due to the coupling of these methyl protons with H-4 and 
fits the characteristic of this methyl group (C-23) at C-4. C-4 showed correlation with H-
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2, H-23 and H-24 and the quaternary carbon C-5 showed correlations with H-1, H-3, H-6 
and H-24. These correlations supported the attachment of C-23 methyl group at C-4 and 
C-24 methyl group at C-5. The methyl protons at H-25 showed correlations with C-8, C-9, 
C-10 and C-11. These correlations supported the attachment of the C-25 methyl group at 
C-9 position. Similarly, the methyl protons at H-26 showed correlations with C-8, C-13, 
C-14 and C-15; the methyl protons at H-27 showed correlations with C-12, C-13, C-14 
and C-18. These correlations allowed us to place the C-26 methyl group at C-15 and C-27 
methyl group at C-13, respectively. The methyl protons at H-28 showed correlations with 
C-16, C-17, C-18 and C-22. These correlations allowed us to place the C-28 methyl 
group at C-17. Finally, C-29 showed correlations with H-19 and H-30; C-30 showed 
correlations with H-19, H-21 and H-29; C-20 showed correlations with H-19, H-21, H-29 
and H-30. C-21 showed correlation with H-22, H-29 and H-30; C-21 showed correlation 
with H-22, H-29 and H-30. All these correlations supported the attachment of both C-29 
and C-30 methyl groups to the same carbon at C-20 and the compound is an oleanane 
type triterpenoid. Other significant HMBC correlations are listed in Table 11. The β-
orientation of the hydroxyl group at C-3 was confirmed by comparing the proton 
coupling constant values at this position with literature values [142,143]. The 3.0 Hz 
coupling between H-3 and H-4 and H-2 confirms the stereochemistry. Melting point 
range was found to be 280.0-282.0 ˚C. These data had good agreements with the reported 








Table 11  












J in Hz 
 
HMBC 
(C → H) 
1 CH2 15.8 α: 1.52 m; β: 1.41 m 3, 10 
2 CH2 35.2 α: 1.86 qd (9.5, 3.0)  
β: 1.56 m 
 
3 CH 72.8 α: 3.73 q-like (3.0) 2, 23 
4 CH 49.2 1.22 m  2, 23, 24 
5 C 37.1  1, 3, 6, 24, 
6 CH2 41.7 α: 1.69 m; β: 0.96 m 24 
7 CH2 17.6 1.36 m 6, 8, 
8 CH 53.2 1.25 m 6, 10, 11, 15, 25, 26 
9 C 48.4  8, 25, 
10 CH 61.4 0.86 dd (12.0, 2.0) 1, 2, 6, 24, 25 
11 CH2 35.3 α: 1.27 m; β: 1.19 m 25 
12 CH2 30.6 1.28 m  27 
13 C 37.8  8, 15, 26, 27 
14 C 39.7  18, 26, 27 
15 CH2 32.3 α: 1.46 m;  β: 1.27 m 8, 26 
16 CH2 36.1 α: 1.52 m; β: 1.31 m 22, 28 
17 C 30.0  15, 18, 19, 28 
18 CH 42.8 1.50 dd (11.0, 6.0)  12, 27, 28  
19 CH2 35.6 α: 1.42 m;  β: 1.11 m 18, 29, 30 
20 C 28.2  19, 21, 29, 30 
21 CH2 32.8 α: 1.45 m; β: 1.25 m 22, 29, 30 
22 CH2 39.3 1.46 dd (12.0, 2.0) 18, 28 
23 CH3 11.6 0.91 d (7.0) 4 
24 CH3 16.4 0.93 s 4, 10 
25 CH3 18.2 0.83 s 8 
26 CH3 18.6 0.98 s 15 
27 CH3 20.1 0.95 s 18 
28 CH3 31.8 0.97 s 18, 22 
29 CH3 35.0 0.92 s 19, 30 









Friedelin (94) was obtained as colourless crystals. The IR spectrum demonstrated the 
presence of ketone functionality (νmax 1719 cm-1) in the molecule. It gave a molecular ion 
peak at m/z 426 in the MS. The 1H NMR spectrum showed signals at high-field region 
corresponding to eight methyl groups and these were confirmed also through HSQC-
DEPT spectrum. The 13C NMR spectrum gave 30 signals; eight methyl, eleven methylene, 
four methine and seven quaternary carbons were sorted by HSQC-DEPT spectrum. The 




                                                            (94) 
Most of the spectral correlations were similar to 3β-friedelinol (66), but the C-3 position 
was assigned for a keto group. Melting point range was found to be 263.1-265.0 ˚C. 







2.2.3 Evaluation of the new compound, 24(E)-ethylidenecycloartanone (93) for 
anticancer potential using selected cancer cell lines in culture 
The pure compound, 24(E)-ethylidenecycloartanone (93), was tested for its cytotoxicity 
against four cancer cell lines viz. LL2 (Murine Lewis lung carcinoma), HL60 (Human 
leukaemia), P388 (Murine lymphocytic leukaemia) and WEHI164 (Murine fibrosarcoma). 
It showed no activity even at a concentration of 100 μg/mL against all the cancer cell 
lines tested, i.e. the IC50 value was >100 μg/mL against all the four cancer cell lines 




Growth inhibition (%) of cancer cell lines at various concentrations of the new compound, 
24(E)-ethylidenecycloartanone (93) 
         _____________________________________________________________ 
 
Cancer cell lines and % of growth inhibition 













      221.00 33.3 (±3.9) 36.6 (±6.0) 25.9 (±0.7) 10.8 (±2.5) 
 
      110.50 22.9 (±6.6) 29.8 (±1.6) 11.0 (±0.9)  5.6 (±0.4) 
 
        55.25 17.4 (±5.5) 12.7 (±1.9) 10.1 (±0.8)  4.1 (±0.1) 
 
        22.10 17.0 (±4.5) 12.2 (±2.3)  6.4 (±1.0)  2.3 (±0.3) 
  
          2.21  2.1 (±6.1)  8.2 (±5.1)  5.4 (±0.6)  2.0 (±0.3) 
 
 
P338: Murine lymphocytic leukaemia; HL60: Human leukaemia; LL2: Lewis lung carcinoma; 
WEHI164: Murine fibrosarcoma; No. of replicates, n = 8 for each concentration; Data show mean 





It showed only 33.3% of growth inhibition with a standard deviation of ±3.9 % on LL2 
cancer cell lines at a concentration of 221.0 μM, the highest concentration tested. The 
percentage of growth inhibitions at a concentration of 110.5, 55.25, 22.10 and 2.21 μM, 
were 22.9 (±6.6), 17.4 (±5.5), 17.0 (±4.5) and 2.1 (±6.1) %, respectively, against LL2 
cancer cell lines. Similarly, with P388 cancer cell lines, the results were comparable to 
that of LL2 cancer cell lines, showing 33.6 (±6.0), 29.8 (±1.6), 12.7 (±1.9), 12.2 (±2.3) 
and 8.2 (±5.1) % growth inhibitions at a concentration of 221.0, 110.5, 55.25, 22.10 and 
2.21 μM, respectively. With WEHI164 cancer cell lines, at a concentration of 221.0, 
110.5, 55.25, 22.10 and 2.21 μM, the percentage of growth inhibitions were 25.9 (±0.7), 
11.0 (±0.9), 10.1 (±0.8), 6.4 (±1.0) and 5.4 (±0.6), respectively. With HL60 cancer cell 
lines the percentage of growth inhibitions were10.8 (±2.5), 5.6 (±0.4), 4.1 (±0.1), 2.3 
(±0.3) and 2.0 (±0.3), respectively, at a concentration of 221.0, 110.5, 55.25, 22.10 and 
2.21 μM. 
 
From Table 12, it was observed that the percentage of inhibition gradually increased with 
increasing concentrations. This indicated that the solvent did not play an adverse effect 
on the experiments at a proportion of 2 drops of CrEL and 0.5 mL of ethanol solvent 
mixture, so further dilutions were made with water (see Experimental Section). However, 
in our earlier attempts to screen the cytotoxicity of the same compound with solvent 
mixture of CrEL and ethanol (1:1) 1 mL each and further dilutions were made with water, 
the results obtained were erratic. This indicated that the solvent, CrEL had played a 
significant role and showed adverse effects at somewhat higher ratio. This is consistent 
with the report that CrEL showed cytotoxic effect at high concentrations in vitro [83]. 
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Some cycloartane-type triterpenoids, mostly in the form of saponins or with several 
functional groups, showed cytotoxic acitivities against several cancer cell lines, viz. 
HepG2 (Hepatocellular carcinoma cells), HL60 (Human leukaemia cells), KB Cells, 
A2780 (Ovarian cancer cells), 26L5 (Murine colon cells), HSC2 (Human oral squamous 
cells), U251 (CNS), PC3 (Prostate cancer cells), HCT15 (Colon carcinoma cells), MCF7 
(Human breast cancer cells), K562 (Leukaemia cancer cells) etc. [141-150]. These results 
indicated that some cycloartane-type compounds are cytotoxic against some cancer cell 
lines. However, the new compound, 24(E)-ethylidenecycloartanone (93), though it is a 
cycloartane-type compound, did not show any activity against a panel of cancer cell lines. 
The new compound, 24(E)-ethylidenecycloartanone (93), has only a ketone functional 
group and one double bond. The lack of functionality would be a probable reason for its 
inactivity on the cancer cell lines tested or it may not induce any inhibition on the cancer 












2.2.4 Deriving Median Lethal Dosage (LD50) of crude extract, chloroform and 
hexane fractions of P. bistorta 
LD50 is a dosage that will cause a death of fifty percent of the experimental animals. We 
assessed the LD50of crude extract, chloroform and hexane fractions of P. bistorta using 
Swiss albino mice and the results are given in Tables 13 and 14.  
 
Table 13 
General behaviours of mice after the administration of 200 mg of plant extract/kg of body 
weight of mice 




   P. bistorta 
   crude extract 
 
 
 Chloroform fraction 
     
   Hexane fraction 
  
Control   
     
     
    1 
Slow respiration and 
sedative; locomotion 
was arrested within a 
few hours of 
administration. 
 
Slow respiration and 
sedative; locomotion 
was arrested within a 
few hours of 
administration. 
 
Slow respiration and 
sedative; locomotion 
was arrested within a 






      
    2 
Death of three mice; 
the live one was dull. 
 
Death of two mice 
and the live mice 
were dull. 
Less active; all mice 




      





























No. of mice used in each group, n = 4; Swiss albino mice of both sexes, each weighing about 30 g, were 
used. Extracts/fractions in DMSO (200 mg of extract/kg of body weight of mice) were administered to 
mice by intraperitoneal injection. Crude extract/fractions were dissolved in 10 mL of 100% DMSO. 








General behaviours of mice after the administration of 150 mg of plant extracts/kg of 
body weight of mice 




   P. bistorta 
   crude extract 
 
 
 Chloroform fraction 
     
   Hexane fraction 
  
Control    
     
     
    1 
Slow respiration and 
sedative; locomotion 
was arrested within a 
few hours of 
administration. 
 
Slow respiration and 
sedative; locomotion 
was arrested within a 
few hours of 
administration. 
 
Slow respiration and 
sedative; locomotion 
was arrested within a 






      
    2 
Death of two mice; 
the live mice were 
dull. 
 
Death of one mouse 
and live mice were 
dull. 
Less active, all mice 




      





























No. of mice used in each group, n = 4; Swiss albino mice of both sexes, each weighing about 30 g, were 
used. Extracts/fractions in DMSO (150 mg of extract/kg of body weight of mice) were administered to 
mice by intraperitoneal injection. Crude extract/fractions were dissolved in 10 mL of 100% DMSO. 
Control group was received DMSO. 
 
The experimental animals were administered with crude extract or fractions by the 
intraperitoneal injection. Those groups treated with extract or fractions showed slow 
respiration, sedative and locomotor behaviours. These behaviours were observed within a 
few hours after the administration; while the control experimental animals were normal 
throughout the experiments. On day two, three animals died in the group in which the 
animals were treated with crude extract and two died in the group in which the animals 
were administered with chloroform; while no animals died in the group in which hexane 
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fraction was treated but they were less active and very dull. On day three the survived 
animals were recovered and the locomotive behaviour was also normal in all the groups 
of experimental animals. The same observations were seen on all other days. The 
experimentation was completed on the fifteenth day and the experimental animals were 
sacrificed. The animal bodies were dissected; no gross abnormalities were observed.  
These experiments showed that the LD50 value of crude extract was less than 200 mg/kg 
of body weight and that of chloroform fraction was 200 mg/kg of body weight; while 
hexane fraction was more than 200 mg/kg of body weight.  
 
The experiment was repeated by preparing the crude extract and fractions concentration 
as 150 mg/kg body weight. The general behaviours of mice were observed as previously. 
On day one, day three and the rest of the days, the observations were the same as 
observed previously. But on day two, two animals died in the group in which the animals 
were treated with crude extract; one died in the group in which the animals were treated 
with chloroform fraction, while in the hexane fraction-treated group, no animals died but 
they were less active and very dull. We did not do any further experimentation with lower 
concentrations. We concluded that the LD50 value of crude extract was 150 mg/kg of 
body weight and that of chloroform extract was 200 mg/kg of body weight; the hexane 






2.3.0 Experimental  
General experimental procedures 
Melting points were determined on a Buchi Melting point B-540 apparatus. IR spectra 
were recorded on a Bio Rad, Class II Laser product. 1H, 13C NMR and 2D NMR spectra 
were recorded on Bruker, 300 and/or 500 MHz spectrometers. Standard microprograms 
supplied by Bruker were used to run 1D and 2D NMR spectroscopy. Chemical shifts 
were reported in parts per million (ppm) with TMS as a reference standard or with 
reference to solvent peaks and coupling constants (J) expressed in hertz. LREIMS were 
measured on a Finnigan/MAT MAT 95 XL-T or VG Micromass 7035. HREIMS were 
measured on Finnigan/MAT MAT 95 XL-T mass spectrometers. HPLC was carried on a 
Waters associates, μ-Porasil (300 x 5 mm) column with a Shimadzu RID-10A, refractive 
index detector. Silica gel 60 (Merck, 0.063- 0.200 m) was used for column chromato- 
graphy. Lichroprep RP-18 (Merck, 40-63 μm) was used for separation and/or purification.  
Precoated silica gel plates (Merck, Kieselgel 60F 254, 0.25 mm or Baker Si250F, 0.25 
mm) were used for preparative TLC and/or analytical TLC. Spots were detected using 
UV light or staining with iodine or by spraying with 50% H2SO4 followed by heating at 
110˚C for 5 minutes. The following instruments were used at the Pharmacology 
laboratory; Biological safety cabinet (NUAIRE, Plymouth, USA), ELX 800 Microplate 
reader (Bio-Tek Instruments Inc., USA), Hemocytometer (Fortuna, Germany), Leitz 
Fluovert microscope (Ernst Leitz Wetzlar GMBH, Germany), Water incubator 
(Everbloom Medical & Scientific Pte. Ltd., Singapore), -86˚C Freezer (Forma Scientific), 
Beckman Avanti J-251 Cenrtifuge (Fullerton, CA, USA), Beckman Optima L-90K and 
Ultracentrifuge (Fullerton, CA, USA). 
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Cell Culture 
The following cancer cell lines were obtained from American Type Cell Culture (ATCC) 
(Manassas, VA, USA). 
P338 (Murine lymphocytic leukaemia cells), HL60 (Human leukaemia cells), MCF7 
(Human breast cancer cells), LL2 (Lewis lung carcinoma cells), HepG2 (Hepatocellular 
carcinoma cells), J82 (Bladder transitional carcinoma cells) and WEHI1640 (Murine 
fibrosarcoma cells) 
 
Cells were cultured in Corning disposable flasks using RPMI-1640 or DEME medium 
supplemented with 5% fetal bovine serum and streptomycin and incubated at 37˚C in a 
humidified atmosphere of 5% CO2. To ensure an exponential growth, cells were 
resuspended in fresh medium every 36h or 48h. Cell concentration and viability were 
determined using the trypan blue exclusion test. 20 μL of cell suspension was taken and 
equal volume of trypan blue solution (0.4%) was added. The number of live cells was 
counted using a Hemocytometer under a Leitz light microscope. The cultured cell lines 
were then diluted to required concentration using medium. 90 μL of cultured cells were 
transferred to each well of a 96 well plate and 10 μL extract of various concentrations 
was added to the cultures and incubated at 37˚C in the humidified atmosphere of 5% CO2. 
On day three, 10 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) solution (5mg/mL) was added to the culture medium [151]. After a further 4h of 
incubation, 100 μL solution of 10% sodium dodecyl sulphate (SDS) in 0.01 N HCl was 
added to each well and the formazan crystals in each well were dissolved. Optical density 
(absorbance) measurements were made with a microplate reader at 570 nm. Cytotoxicity 
was calculated by the following formula [152]. 
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Growth inhibition, (GI) = [(OD570 of control – OD570 of test sample)/ OD570 of control] x 
100%. 
 
Preparation of solutions for cell culture study 
The extracts or their sub-fractions were first dissolved in a minimum quantity of (0.5 or 
1.0 mL) dimethylsulfoxide (DMSO) and then diluted to required quantity by water. A 
stock solution of DMSO/water solvent mixture of same proportion was prepared and used 
for subsequent dilutions. DMSO/water solvent mixture of the same proportion without 
extract or sub-fractions served as negative control. In all cases, the proportion of DMSO 
was kept constant.  
 
The new compound, 24(E)-ethylidenecycloartanone (93) is highly hydrophobic; it is 
insoluble in DMSO which is the solvent mainly used for cytotoxic screening in the MTT 
assay. Therefore we used a CrEL/ethanol solvent mixture at the first, followed by water. 
10 mg of the new compound (93) was first dissolved in a minimum quantity of CrEL (2 
drops) and 0.5 mL of ethanol solvent mixture. The solution was stirred with a spatula in 
order to attain homogeneity and the solution was made up to 10 mL using water and was 
shaken well. As per calculation, this served as a solution of concentration 221.0 μM (100 
μg/mL). A stock solution of CrEL/ethanol solvent mixture and water of the same 
proportion was prepared and used for subsequent dilutions. A total of five concentrations, 
221.0, 110.5, 55.25, 22.1 and 2.21 μM (i.e.100, 50, 25, 10 and 1 μg/mL) were prepared. 
CrEL/ethanol solvent mixture and water of the above mentioned proportion without 
compound was served as negative control.  
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Experimental animals for toxicity study 
White Swiss albino mice of both sexes weighing about 30g each were used. The animals 
were divided into four groups, each consisting of four animals. The first three groups 
were treated with the crude extract or fractions while the fourth one served as a control 
group. A solution of crude extract, hexane and chloroform fractions were prepared in 10 
mL of 100% DMSO and administered to each mouse by intraperitoneal injection. The 
solutions were prepared by dissolving them as per the ratio of 200 mg of extracts/kg 
bodyweight of mice in 10 mL of 100% DMSO. Their general behaviours were assessed 
after the administration (by intraperitoneal injection) of the extract or fractions as 
reported in the literature [153,154]. The experimental animals were sacrificed on the 
fifteenth day. We repeated the experiments by administering the crude extract, hexane 
and chloroform fractions of 150 mg extract/kg of body weight of mice in 10 mL of 100% 
DMSO. The general behaviours of experimental mice were monitored as previously; the 
animals were sacrificed on the fifteenth day. 
 
Plant Material 
The plant materials were purchased from a local market and a voucher specimen (KMano 
PB 2003) is deposited in the Department of Biological Sciences, National University of 
Singapore, Singapore. 
 
Extraction and Isolation  
The rhizomes of P. bistorta (600g) were ground into powder and then extracted with 
chloroform (3L x 4) at room temperature. The residue was dissolved in a water/methanol 
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mixture (95:5) and was then extracted successively with hexane and chloroform. After 
the preliminary screening followed by the isolation of 24-methylenecycloartanone (97), 
we carried out further investigation by purchasing 12 kg of plant material and extracted it 
as previously. Rota-vapour was used to remove solvent from hexane and chloroform 
fractions.  The hexane extract was chromatographed over silica gel using hexane and 
eluted in a gradient fashion with increasing polarity. Purification of the eluted fractions 
afforded friedelin (94) (6 mg), β-sitosterol (47) (1.2 g), γ-sitosterol (96) (4 mg), 24(E)-
ethylidenecycloartanone (93) (580 mg) and cycloartane-3,24-dione (95) (ca.1.5 mg). The 
chloroform extract was chromatographed over Lichroprep RP-18 and eluted in isocratic 
fashion with methanol. Purification of eluted fractions afforded β-sitosterol (47) (110 mg), 
β-sitosterone (100) (ca. 0.5 mg), 24(E)-ethylidenecycloartanone (93) (7.0 mg) and 24(E)-
ethylidenecycloartan-3α-ol (98) (ca. 1.0 mg). For methanol-water fraction, Rota-vapour 
was used first to remove as much solvent as possible followed by the use of Freeze 
dryer/Lyophilizer to remove the remaining solvent. The residue was chromatographed 
over Lichroprep RP-18 and eluted in isocratic fashion with methanol. Purification of one 
of the eluted fractions afforded β-sitosterol (47).  
 
List of spectral data and physical properties of compounds 
24(E)-Ethylidenecycloartanone (93) 
Colourless crystals; mp 135.4-137.1 ˚C; IR (KBr) vmax 3046, 2939, 2864, 1712, 1448, 
1376 cm-1; MS (EI, 70eV), m/z (rel.int. %):  452 [M]+ (72), 437 (42), 354 (86), 340 (48), 
313 (72), 271 (44), 216 (78), 175 (51), 95 (100), 55 (54); HREIMS m/z 452.4019 (calcd. 
for C32H52O, 452.4018); 1H and 13C NMR data: see Table 6.   
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24(E)-Ethylidenecycloarta-3α-ol (98)  
Colourless solid; MS (EI, 70eV), m/z (rel.int. %): 454 [M]+ (72), 437 (42), 354 (86), 340 
(48), 315 (72), 271 (44), 216 (78), 175 (51), 95 (100), 55 (54); HREIMS m/z 454.4175 
(calcd for C32H54O, 454.4174); 1H and 13C NMR data: see Table 7. 
24,31-Epoxy-24-ethylcycloartan-3α-ol (99)  
Colourless amorphous powder; MS (EI, 70eV), m/z (rel.int. %): 470 [M]+ (8), 454 (48), 
439 (64), 356 (33), 315 (45), 271 (44), 201 (78), 175 (92), 95 (100), 55 (60); HREIMS 
m/z 470.4108 (calcd. for C32H52O, 470.4123); 1H and 13C NMR data: see Table 8. 
Cycloartane-3,24-dione (95) 
Colourless crystals; MS (EI, 70eV), m/z (rel.int. %):  440 [M]+ (84), 425 (61), 407 (21), 
379 (19), 354 (78), 342 (30), 313 (100), 302 (59), 271 (20), 203 (66), 175 (84), 135 (87), 
127 (77); HREIMS m/z 440.3655 (calcd for C32H52O, 440.3654); 1H and 13C NMR data: 
see Table 9.  
24-Methylenecycloartanone (97) 
Colourless crystals; mp 111-113 ˚C; IR (KBr) vmax 3040, 2939, 2862, 1712, 1376, 1442, 
814 cm-1; MS (EI, 70eV), m/z (rel.int. %): 438 [M]+ (100), 423 (47), 395 (31), 355 (28), 
340 (40),313 (75), 300 (39), 219 (34),175 (54), 147 (49), 95 (68), 69 (28), 55(15); 1H and 
13C NMR data: see Table10. 
 β-Sitosterol (47) 
Colourless flakes; mp.136.1-138 ˚C; IR (KBr) vmax 3429, 2960, 2880, 1662, 1464, 1377, 
1330, 1049 cm-1; MS (EI, 70eV), m/z (rel.int. %): 414 [M]+ (64), 396 (100), 381 (42), 303 
(30), 255 (50), 231 (40), 173 (18), 145 (78),121 (46), 107 (56), 81 (40), 55 (38); 1H-NMR 
(CDCl3) δ 1.15 m, Hα, 1.89 m, Hβ (H-1), 1.85 m, Hα, 1.56 m, Hβ , (H-2), 3.52 (1H, m, 
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H-3), 2.28 m (2H, H-4), 5.36 (1H, br d, 5.4 Hz, H-6), 1.53 m (2H, H-7), 1.93 m (1H, H-8), 
0.98 m (1H, H-9), 1.51 m (H-11), 2.03 m, Hα, 1.19 m, Hβ (H-12), 1.00 (1H, H-14), 1.61 
m, Hα, 1.13 m, Hβ, (H-15), 1.86 m, Hα, 1.35 m, Hβ, (H-16), 1.10 (1H, H-17), 0.68 (3H, s, 
H-18), 1.01 (3H, s, H-19), 1.37 m (1H, H-20), 0.92 (3H, d, 6.4 Hz, H-21), 1.35 m, Hα, 
1.04 m, Hβ (H-22), 1.20 m (2H, H-23), 0.97 m (1H, H-24), 1.70 m (1H, H-25), 0.83 (3H, 
d, 6.8 Hz, H-26), 0.81(3H, d, 6.4 Hz, H-27),1.27(1H, H-28), 0.845 (3H, t, 6.6 Hz, H-29); 
13C-NMR (CDCl3) δ37.2 (C-1), 31.6 (C-2), 71.8 (C-3), 42.3(C-4), 140.8 (C-5), 121.7 (C-
6), 31.8 (C-7), 31.9 (C-8), 50.1 (C-9), 36.5 (C-10), 21.1 (C-11), 39.7 (C-12), 42.3 (C-13), 
56.8 (C-14), 24.3 (C-15), 28.2 (C-16), 56.1 (C-17), 11.9 (C-18), 19.4 (C-19), 36.1 (C-20), 
18.9 (C-21), 33.9 (C-22), 26.0 (C-23), 45.8 (C-24), 29.1 (C-25), 19.8 (C-26), 19.0 (C-27), 
23.0 (C-28), 12.0 (C-29). 
γ-Sitosterol (96) 
Colourless crystals; mp147-148 ˚C; MS (EI, 70eV), m/z (rel.int. %): 414 [M]+ (16), 145 
(45), 95 (100), 83 (26), 93 (85), 71 (46), 55 (27). 
β-Sitosterone (100) 
Amorphous solid; MS (EI, 70eV), m/z (rel.int. %): 412 [M]+ (90), 397 (32), 370 (60), 327 
(28), 289 (70), 271 (42), 229 (96), 187 (30),149 (64), 124 (100), 69 (32), 55 (38) 43 (46); 
[60]. 
3β-Friedelinol (66) 
Colourless crystals; mp 280-282 ˚C; IR (KBr) vmax 3500, 1380, 1370, 1265, 1175, 1020, 
800 cm-1; MS (EI, 70eV),   m/z (rel.int. %): 428 [M]+ (215), 413 (27), 275 (46) 248 (26), 
231 (52), 220 (42), 205 (53), 177 (57), 165 (82),  125 (98), 95 (100), 69 (76), 55(34); 1H 
and 13C NMR data: see Table 11. 
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Friedelin (94) 
Colourless crystals; mp 263-265 ˚C; IR (KBr) vmax 2946, 2882, 2869, 1719, 1464, 1385 
cm-1; MS (EI, 70eV), m/z (rel.int. %): 426 [M]+ (28), 341 (12), 302 (32), 273 (54), 231 
(38), 205 (56), 191 (44), 163 (57), 13 (100), 109 (98), 69 (75), 55 (43); 1H NMR (CDCl3) 
δ 1.95, 1.71, (2H, ddd, H-1), 2.37, 2.27 (2H, ddd, H-2), 2.25 (1H, q, H-4), 1.73,1.28 (2H, 
d, H-6), 1.49, 1.36 (2H, m, H-7), 1.38 (1H, dd, H-8), 1.53 (1H, m, H-10), 1.45, 1.26 (2H, 
m, H-11), 1.33, 1.33 (2H, m, H-12), 1.47, 1.27 (2H, m, H-15), 1.58, 1.35 (2H, m, H-16), 
1.56 (1H, m, H-18), 1.37, 1.21 (2H, m, H-19), 1.50, 1.31 (2H, m, H-21), 1.50, 0.94 (2H, 
m, H-22), 0.88 (3H, d, H-23), 0.71 (3H, s, H-24), 0.86 (3H, s, H-25), 1.00 (3H, s, H-26), 
1.04 (3H, s, H-27), 1.17 (3H, s, H-28), 0.99 (3H, s, H-29), 0.94 (3H, s, H-30); 13C NMR 
(CDCl3) δ22.3 (C-1), 41.5 (C-2), 213.2 (C-3), 58.2 (C-4), 42.1 (C-5), 41.3 (C-6), 18.2 (C-
7), 53.1 (C-8), 37.4 (C-9), 59.4 (C-10), 35.6 (C-11), 30.5 (C-12), 39.7 (C-13), 38.3 (C-14), 
32.4 (C-15), 36.0 (C-16), 30.0 (C-17), 42.8 (C-18), 35.3 (C-19), 28.1 (C-20), 32.7 (C-21), 
39.2 (C-22), 7.2 (C-23), 15.0 (C-24), 17.9 (C-25), 20.2 (C-26), 18.6 (C-27), 32.1 (C-28), 











Constituents of Eugenia grandis (Myrtaceae) 
3.1.0 Introduction to Myrtaceae family 
The genera Syzigium and Eugenia both belong to the Myrtaceae family and consist of 
approximately 700 species confined mainly to the warmer parts of the world [155]. 
The genus Eugenia consists of approximately 600 species in the tropics.  These trees or 
shrubs are often planted for ornaments in warm regions with species yielding edible fruits 
[155]. A number of species have been reported to contain triterpenes and/or β-sitosterol 
(47) [156]. Examples of triterpenoids isolated were arjunolic acid (102), asiatic acid (103),  
methyl arjunolate (104), methyl asiatate (105), lupeol (106), betulinic acid (65),  α- 
amyrin (107) , β-amyrin (108), methyl 2α-acetoxy-3β-hydroxyolean-12-en-28-oate (109), 
methyl 2α-acetoxy-3β-hydroxyurs-12-en-28-oate (110), 2α-hydroxyursolic acid (111), 
methyl maslinate (methyl 2α,3β-dihydroxyolean-12-en-28-oate) (112), methyl 2α,3β-
dihydroxyurs-12-en-28-oate (113), oleanolic acid (46), epioleanolic acid (114), ursolic 
acid (115), epiursolic acid (116), crategolic acid (117), erythrodiol (118), friedelin (94) 
and 3β-friedelinol (66) [156-159]. The only steroid isolated was β-sitosterol (47).  
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Eugenia aromatica (syn: Syzigium aromaticum, Eugenia caryophyllata, Caryophyllus 
aromaticus), Jambosa caryophyllus, Eugenia jambolana (syn: Syzigium cumini), Eugenia 
maire, Eugenia fructicosa, Eugenia wallichii, Syzigium cordatum, Eugenia javanica (syn: 
Syzigium samarangense, Eugenia formosa), Eugenia mooniana, Eugenia biflora etc. are 
some examples of species belong to the Myrtaceae family. Among the Eugenia species, 
Eugenia caryophyllata has been most extensively studied due to its medicinal properties 
and economic values. Extracts from the plant have been used in treating tooth ache and 
gum diseases, dandruff control, antibaldness, scalp-treatment, transdermal and antitumour 
pharmaceuticals, food flavourings and as antioxidants for fats.  
3.1.1 Introduction to Eugenia grandis 
Eugenia grandis (syn. Syzygium grande) (Myrtaceae) also known locally as Sea apple or 
Jambu Laut, is a common seashore tree. They are often planted along the roadsides to 
give shade. The trees are tall, growing to 30 m and have an irregular crown. The leaves 
are large, shiny, dark green, elliptic in shape and have a distinct down-turned tip. The 
flowers are oblong, large, white and fluffy.   
3.1.2 Previously reported chemical constituents from E. grandis 
A thorough literature search indicated that there was only one report on the chemical 
constituents of E. grandis. The isolation of castalagin (119), vescalagin (120) and 
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3.2.0 Results and Discussion 
We investigated the chloroform extract of stem-bark of E. grandis for their chemical 
constituents. A new compound, 2α,3β-dihydroxylup-12-en-28-oic acid (122), a rarely 
encountered compound, 3β-hydroxylup-12-en-28-oic acid (123), a mixture containing 
two known compounds viz. arjunolic acid (102) and asiatic acid (103) together with other 
five known compounds, fridelin (94), 3β-friedelinol (66), β-sitosterol (47), oleanolic acid 
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3.2.1 Characterisation of the isolated chemical constituents from E. grandis 
2α,3β-Dihydroxylup-12-en-28-oic acid (122) 
2α,3β-Dihydroxylup-12-en-28-oic acid (122) was obtained as colourless crystals. The 
molecular formula was determined to be C30H48O4 by high-resolution EIMS (m/z 
472.3549). The IR spectrum gave absorption peaks at νmax 3437, 1692 and 1642 cm-1; 
these are characteristic of hydroxyl, carboxyl and double bond respectively.  The 13C 
NMR gave thirty signals. Seven methyl, eight methylene, eight methine and seven 
quaternary carbons were sorted by HSQC-DEPT spectrum. Two of the methine carbon 
signals were observed at δ 68.6 and 83.6 indicating the presence of two hydroxyl groups. 
Further, the chemical shift values of another methine and a quaternary carbon were 
observed at δ 125.8 and 138.7, respectively, indicated the presence of a double bond. One 
of the quaternary carbons showed a chemical shift value at δ 180.9 indicated the presence 
of a carboxylic group. The ring olefinic double bond and the fact that the compound has a 
lup-12-ene skeleton was indicated by resonances of the sp2 carbons C-12 (methine) at δ 
125.8  and C-13 (quaternary carbon) at δ 138.7 and by the analysis of the methine and 
methylene resonances. In the HMBC spectrum, it is evident that the signal at δ 5.26 (t, 
3.6, Hz) attributed to hydrogen H-12, which is also a typical feature of ring olefinic 
proton [161], showed correlations with carbon signals at C-9, C-11, C-14 and C-18. 
Similarly, C-13 showed correlations with H-11, H-15, H-18 and H-27. Therefore, the 
olefinic double bond was placed between C-12 and C-13 based on these correlations. 
Further, the carboxyl group was attached at C-17, since C-28 (δ 180.9) assigned for the 
carboxyl group showed correlations with H-16 and H-18. The position of the double bond 
and the carboxyl group was collectively supported by an MS fragmentation peak at m/z 
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248 (base peak), which was due to retro Diels-Alder cleavage of the molecule as shown 
in Scheme 3. Other fragmentation peaks were observed at m/z 203, 189 and 133 (Scheme 
3). These are characteristics of a lupane or oleanane or ursane-type triterpenoids [161-
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The 1H NMR spectrum showed signals at δ 3.64 (ddd, J = 11.3, 9.9, 4.6 Hz, 1H) and 2.93 
(d, J = 9.9 Hz, 1H) ascribable to two hydroxymethine protons. Through analysing HSQC 
and HMBC spectra, these two hydroxymethine protons were respectively assigned as H-2 
and H-3.  In the HMBC spectrum, it is evident that the H-2 proton (δ 3.64) showed 
correlations with C-10 and H-3 proton (δ 2.93) showed correlations with C-23 and C-24. 
Further, H-2 has a β-orientation while H-3 has an α-orientation. In other words the 
hydroxyl group at C-2 position has the α-orientation while it has the β-orientation at C-3 
position. These orientations were confirmed through NOESY and comparing their 
coupling constant values and/or multiplicity with related compounds [164-166]. The 
NOESY correlations of H-2 with H-24 and H-25; H-3 with H-5 and H-23, indicated the 
relative configurations at C-2 and C-3. Other significant correlations observed were H-9 
with H-5 and H-27; H-11 with H-12 and H-25; H-24 with H-25 and H-25 with H-11 and 
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H-24. With all these information, the structure of this new compound was derived as 

























Scheme 3  


















 J in Hz 
 
HMBC 
(C → H) 
 
NOESY 
   
1 CH2 47.4 α: 1.98 m  
β: 0.92 m 
9, 25   
2 CH 68.6 β: 3.64 ddd  
(11.3, 9.9, 4.6) 
3 24, 25 
3 CH 83.6 α: 2.93 d (9.9) 2, 23, 24 5, 23 
4 C 39.5  23, 24, 25  
5 CH 55.8 0.87 m 1, 23, 24  
6 CH2 18.6 α: 1.58 m 
β: 1.45 m 
5, 7  
7 CH2 33.3 α: 1.38 m  
β: 1.58 m 
5, 26  
8 C 39.8  6, 7, 9, 11, 26  
9 CH 48.0 1.63 m 5, 11, 12, 25, 26 5, 27 
10 C 38.2  2, 5, 11, 25  
11 CH2 23.6 α: 1.99 m 
β: 1.99 m 
9, 12 12, 25 
12 CH 125.8 5.26 t (3.6) 11, 18  
13 C 138.7  11, 15, 18, 27  
14 C 42.2  9, 12, 15, 18,  26   
15 CH2 28.3 α: 1.95 m   
β: 1.11 m 
16, 27  
16 CH2 24.4 α: 2.06 m  
β: 1.67 m 
15, 18, 22  
17 C 48.2  15, 18, 19  
18 CH 53.5 2.30 d (11.6)  12, 16, 19   
19 CH 39.5 1.41 m 18, 29, 30  
20 CH 39.6 1.00 m 18, 19, 29, 30  
21 CH2 30.9 α: 1.52 m 
β: 1.37 m 
22  
22 CH2 37.2 α: 1.72 m 
β: 1.66 m 
  
23 CH3 28.5 0.83 s 3, 24  
24 CH3 16.6 0.83 s 3, 23 25 
25 CH3 16.3 1.04 s 1, 9 11, 24 
26 CH3 16.9 0.87 s 9  
27 CH3 23.2 1.15 s 15  
28 C 180.9  16, 18, 22  
29 CH3 20.7 0.99 d (6.5) 19, 30  





3β-Hydroxylup-12-en-28-oic acid (123) 
3β-Hydroxylup-12-en-28-oic acid (123) was obtained as colourless crystals. The 
molecular formula was determined to be C30H48O3 by high-resolution EIMS (m/z 
456.3588). The IR spectrum gave absorption bands at νmax 3406, 1689 and 1639 cm-1; 
these are characteristics of hyrdroxyl, carboxyl and double bond, respectively. The 13 C 
NMR gave thirty signals; seven methyl, nine methylene, seven methine and seven 
quaternary carbons were sorted by HSQC-DEPT spectrum. The 13 C NMR signal of a 
methine carbon was observed at δ 79.0 indicated the presence of hydroxyl functionality. 
The chemical shift values of another methine and a quaternary carbon were observed at δ 
126.1 and 138.8, respectively, indicated the presence of a double bond. One of the 
quaternary carbons showed a chemical shift value at δ 181.1 that indicated the presence 




                                                               (123) 
Its mass spectrum gave a base peak at m/z 248 and other fragmentation peaks at m/z 235, 
203, 189 and 133, which is a characteristic of a lupane or oleanane or ursane-type 
triterpenoids with C-12 unsaturation and a carboxyl group at C-17 position. Most of the 
HMBC spectral correlations have close similarity with compound, 2α,3β-dihydroxylup-
12-en-28-oic acid (122) except at C-2 position in which the hydroxyl group is absent. The 
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signal observed at δ 3.71 (dd, J = 11.6, 4.8 Hz) was diagnostic for H-3, deducing from an 
HMBC correlations between H-23 (δ 0.98), H-24 (δ 0.77) and C-3 (δ 79.0). The chemical 
shift value and J couplings (diaxial and axial/equatorial interactions) suggested the 
presence of a β-hydroxyl substitution at C-3 [161]. The same compound (123) has been 
reported twice previously [161,167]. However, complete NMR data were not given in 
both reports, as well as to the best of our knowledge, assignments were not found from 































J in Hz 
 
HMBC 
(C → H) 
1 CH2 39.2 α: 1.66 m; β: 1.66 m 5, 25 
2 CH2 27.1 α: 1.63 m; β: 1.58 m  
3 CH 79.0 α: 3.71 dd (11.6, 4.8) 1, 23, 24 
4 C 39.2  5, 23, 24 
5 CH 55.2 0.74 m 1, 6, 23, 24, 25 
6 CH2 18.8 α: 1.54 m; β: 1.38 m 5 
7 CH2 33.5 α: 1.53 m; β: 1.35 m 5, 9, 26 
8 C 40.1  6, 7, 9, 11, 26 
9 CH 48.1 1.54 m 7, 11, 12, 25, 26 
10 C 37.4  2, 5, 6, 9, 11, 25 
11 CH2 23.7 α: 1.92 m; β: 1.92 m 9, 12 
12 CH 126.1 5.24 t (3.6) 11, 18 
13 C 138.8  11, 18, 27 
14 C 42.9  9, 12, 15, 18, 26, 27 
15 CH2 28.4 α: 1.90 m;  β: 1.09 m 16, 27 
16 CH2 24.6 α: 2.02 m; β: 1.65 m 15, 18 
17 C 48.3  15, 16, 18, 19 
18 CH 53.4 2.19 d (11.5) 12, 19  
19 CH 39.6 1.36 m 18, 20, 29, 30 
20 CH 39.5 0.99 m 19, 29, 30 
21 CH2 31.1 α: 1.50 m; β: 1.33 m  
22 CH2 36.3 α: 1.70 m; β: 1.64 m  
23 CH3 28.2 0.98 s 3, 5, 24 
24 CH3 15.8 0.77 s 3, 5, 23 
25 CH3 15.6 0.96 s 1, 5, 9 
26 CH3 17.1 0.84 s 9 
27 CH3 23.7 1.11 s 15 
28 C 181.1  16, 18 
29 CH3 21.2 0.95 d (6.5) 30 








Mixture of two compounds (102) and (103) 
The mixture of two compounds, arjunolic acid (102) and asiatic acid (103), were obtained 
as colourless crystals. Both compounds have the same molecular formula, C30H48O5, 
deduced from HREIMS m/z 488.3497. The EIMS gave a single molecular ion peak at m/z 
488 and a base peak at m/z 248 gave information about the presence of a pentacyclic 
triterpenoids. We have confirmed this molecular ion peak with ESI and FAB mass 
spectroscopy. Both gave [M-1]+ ion at m/z 487. However, there was inconsistency in the 
observed molecular weight and the number of 13C NMR signals. In the 13C NMR 
spectrum, we observed more than forty peaks. Some peaks displayed doublets with 
unequal intensities, which were not due to incomplete 1H-decoupling. For example, a 
peak at about δ 181, which indicated the carboxyl carbon, showed two very close signals 
at δ 180.9 and 181.1. Further, both HMBC and HSQC-DEPT gave peaks with stacking 
one over another or with very close chemical shift values. Based on these observations, 
we understood that it was a mixture of two closely related compounds. The MS 
fragmentation pattern has close similarity to the new compound, 2α,3β-dihydroxylup-12-
en-28-oic acid (122) except a mass difference of 16 amu. This observation allowed us to 
assume the presence of an extra hydroxyl group in the sample compared to the new 
compound, 2α,3β-dihydroxylup-12-en-28-oic acid (122). As expected, on inspection of 
its chemical shift values in 13C and DEPT spectra at the hydroxyl region, three 
oxygenated carbons were observed, one at δ 75.2 another at δ 66.8, both attached to 
methine carbons with the third one at δ 63.3 attached to a methylene carbon. However 
each of the three peaks displayed two peaks with a negligibly small chemical shift 
difference. We have placed one hydroxyl group at C-2 and another group at C-3 based on 
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the spectral correlations obtained in the new compound, 2α,3β-dihydroxylup-12-en-28-
oic acid (122). According to the number of different types of carbons, the third hydroxyl 
group, as it attached to methylene carbon, should replace any one of methyl hydrogens, 
so that it will form –CH2OH group.  It is impossible to use all other positions which will 
make the carbon either methine or quaternary. 
 
As mentioned earlier that EIMS gave a base peak at m/z 248 and other fragment peaks at 
m/z 203, 189 and 133 indicative of lupene or oleanene or ursene type triterpenoids with a 
double bond between C-12 and C-13 and a carboxyl group at C-17 position. This 
observation allowed us to exclude the presence of a hydroxyl group in rings C, D and E. 
Any changes in any one of the position in these rings will not follow this fragmentation 
pattern.  In other words, it is impossible to utilise the methyl group present in these rings 
for the formation of –CH2OH. The only possibility is to utilise one of the methyl groups 
present in ring A or B i.e. C-23, C-24, C-25 and C-26. Inspection of its HMBC revealed 
that the single proton at C-3 position correlates with an oxygenated methylene carbon at 
C-23 position. This allowed us to exclude the possibility of C-24, C-25 and C-26 
positions. This is consistent with reports of NMR signals of methyl groups of pentacyclic 
triterpenoids with oxygen functions at 2, 3 and 23 positions [168].   
 
For this interpretation, three structures are possible, viz. 2α,3β,23-trihydroxyolean-12-en-
28-oic acid (arjunolic acid) (102), 2α,3β,23-trihydroxyurs-12-en-28-oic acid (asiatic acid) 































                                                              (124) 
We were unable to get the two possible structures based on their 2D NMR spectral 
correlations, due to their extreme complexity, in particular at the high-field region. 
However, analysis of its 13C NMR or DEPT spectrum in the olefinic region showed that 
peaks were not stacked one over another; we observed four independent peaks with 
reasonably good chemical shift difference. Further, it was also observed that two of them 
were methine and the other two were quaternary carbons. These peaks were due to C-12 
and C-13 positions. The chemical shift values of one of the methine and a quaternary 
carbon were observed at δ 122.6 and 144.6, respectively. These values were in very good 
agreement with chemical shift values of arjunolic acid (102) at its C-12 and C-13 
positions. Similarly the chemical shift values of another methine and a quaternary carbon 
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were observed at δ 125.9 and δ 139.0, respectively. These values were in very good 
agreement with chemical shift values of asiatic acid (103) at its C-12 and C-13 positions.  
 
As stated earlier that the 13C NMR and HMBC spectra were very complicated at the high-
field region; we were unable to get the chemical shift values for the individual 
compounds. Thus, we tentatively assigned that the mixture of two compounds were 
arjunolic acid and asiatic acid. Our literature search indicated that reports of a mixture 
containing two compounds are very common, in particular the pentacyclic triterpenoids 
[169,170]. Our literature search also revealed that the existence of the compound, 
2α,3β,23-trihydroxylup-12-en-28-oic acid (124) has not been reported so far. Further, 
oleanane- and ursane-type compounds were reported as a mixture rather than lupane & 
oleanane or lupane & ursane [169,170]. The NMR chemical shift values for the 
individual compounds and/or their methyl esters are available in the literature [171-175]. 
 
Arjunolic acid (102) and its semisynthetic derivatives were shown to exhibit inhibitory 
effects on Epstein-Barr virus (EBV) activation in Raji cells. Arjunolic acid derivatives 
could be valuable compounds as antitumour-promoters.  Their inhibitory effects on skin 
tumour promoters were greater than those of previously studied natural products 
[176,177]. The anticancer effect of asiatic acid in two human breast cancer cell lines, 
MCF7 and MDA-MB-231 was reported earlier.  Asiatic acid exhibited effective cell 
growth inhibition by inducing cancer cells to undergo S-G2/M phase arrest and apoptosis 
[178]. Asiatic acid (103) decreased viability and induced apoptosis in SK-MEL-2 
(Human melanoma cells) and HepG2 (Human hepatoma cells) in a time- and dose-
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dependent manner [179,180]. Asiatic acid dose-dependently showed cytotoxicity in 
HT29 (Human colon adenocarcinoma cell lines). The structural relationships of asiatic 
acid (103) and its derivatives to cytotoxicity and antihepatofibrotic activity in HSC-T6 
cells were reported.  Modification of the carboxylic acid group at C28 also reduced the 
cytotoxicity in HSC-T6 cancer cell lines [181].   
 
Oleanolic acid (46) 
Oleanolic acid (46) was obtained as colourless crystals. The mass spectrum of the 
compound showed molecular ion peak at m/z 456. The 13 C NMR gave thirty signals; 
seven methyl, ten methylene, five methine and eight quaternary carbons were sorted by 
DEPT analysis. A methine carbon showed a chemical shift value at δ 78.2, indicated the 
presence of hydroxyl functionality. The chemical shift values of another methine and a 
quaternary carbon were observed at δ 122.6 and 144.8 respectively indicated the presence 
of a double bond. One of the quaternary carbons showed the chemical shift value at δ 




                                                                (46) 
The mass spectrum gave a base peak at m/z 248 and other fragmentation peaks at m/z 235, 
203, 189 and 133, which are characteristic of a lupene- or oleanene- or ursene-type 
triterpenoids with C-12 unsaturation and a carboxyl group at C-17 position. The single 
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hydrogen at C-12 gave a chemical shift value centered at δ 5.49 (t, J = 3.6 Hz) in the 1H 
NMR spectrum, which is a typical feature of ring olifinic proton [167]. A peak at δ 3.45 
(dd, J = 11.2, 4.6 Hz) is due to H-3. Melting point range was found to be 196-198 ˚C. 
Comparison of its spectral data with those reported in the literature had good agreement 
[162,182-184].  
 
Oleanolic acid (46) and ursolic acid (115) are pentacyclic triterpenoic acids having 
closely related chemical structure and are the major components of some traditional 
herbal medicines. There is a growing interest in the evaluation of the biological roles of 
these triterpenoid compounds. A review paper summarised the biological activities of 
triterpenoid acids (anti-inflammatory, hepatoprotective, gastroprotective, anti-ulcer, anti-
HIV, cardiovascular, hypolipidemic, antiatherosclerotic and immunoregulatory effects) 
[185]. Oleanolic acid (46) is relatively non-toxic and could be used as chemopreventive/ 
chemoprotective agents in clinical practice [185,186]. The IC50 values for oleanolic acid 
on HCT15 (Human colon carcinoma cell lines) was 60 μmol/L. Proliferation assay 
showed that proliferation of oleanolic acid-treated cells was slightly increased at 24 h and 
significantly decreased at 48 h and 60 h. [187]. The IC50 values of oleanolic acid on WI 
38, VA13 and HepG2 cancer cell lines were 14.5, 123 and 165 μM, respectively [188]. 
Oleanolic acid has been shown to inhibit mouse skin tumour promotion and showed 
bioactivity against a panel of 6 human solid tumour cell lines [189]. 
 
Betulinic acid (65) 
Betulinic acid (65) was obtained as colourless crystals. The 13 C NMR gave thirty signals; 
six methyl, eleven methylene, six methine and seven quaternary carbons were sorted by 
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DEPT analysis. A methine carbon showed the chemical shift value at δ 78.2 indicated 
the presence of a hydroxyl group. The 1H NMR spectrum showed a peak at δ 3.5 (t, J = 




                                                               (65) 
 The chemical shift values of a methylene and a quaternary carbon were observed at δ 
110.0 and 151.0, respectively, indicated the presence of a double bond. One of the 
quaternary carbons showed a chemical shift value at δ180.0 in the 13C NMR indicated the 
presence of a carboxylic group.  Two peaks as singlet at δ 4.95 (s) and 4.77 (s) in the 1H 
NMR spectrum are characteristics of end methylene hydrogens. Comparison of its 
spectral data with those reported in the literature had good agreement [162,190]. 
 
Betulinic acid (3-hydroxy-lup-20(29)-en-28-oic acid) (65) is a pentacyclic lupane-type 
triterpenoid that is widely distributed in the plant kingdom. A variety of biological 
activities has been ascribed to betulinic acid (65). With regard to its anticancer properties, 
it exhibited selective cytotoxicity against several melanoma-derived cell lines; because of 
its selective cytotoxicity against tumour cells and favourable therapeutic index, betulinic 
acid is a very promising new chemotherapeutic agent for the treatment of cancer. To date, 
dihydrobetulinic acid is a most potent pentacyclic triterpenoid to inhibit eukaryotic 
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topoisomerase I with IC50 value of 0.5 μM and can be exploited as a strong candidate for 
anti-tumour drug design [191-200].  
 
Betulinic acid (65) inhibited the growth of K562 tumour cell lines with IC50 values 6.25 
μg/mL and induces apoptosis in leukemia cells and further evaluation as a future drug to 
treat leukemia is on [196, 201-203]. Betulinic markedly inhibited cell growth of A-549, 
SK-OV-3, SK-MEL-2, XF498 and HCT15 human tumour cells [204]. The IC50 values of 
betulinic acid (65) on WI 38, VA13 and HepG2 cancer cell lines were respectively 1.3, 
11.6 and 21μM [188].   
 
β-Sitosterol (47), friedelin (94) and 3β-friedelinol (66) 













3.3.0 Experimental  
General experimental procedure was followed elsewhere as described in chapter 2 
Plant Material 
The plant material was collected in Singapore along Kent Ridge Road and identified by 
Associate Prof. Hugh Tan Tiang Wah, Dept. of Biological Sciences, NUS and Chua 
Keng Soon, Senior Laboratory Officer (RMBR), Herbarium, NUS. A voucher specimen 
(KM20041122) was deposited in the herbarium, Department of Biological Sciences, 
National University of Singapore, Singapore. 
Extraction and Isolation  
A whole plant weighing about 20 kg (wet weight) was cut and chopped into small pieces. 
The air-dried material was then exhaustively extracted with chloroform and the extract 
was chromatographed over silica gel using hexane and eluted with the solvents of 
increasing polarity. Further purification of eluted fractions by repeated column 
chromatography and/or preparative TLC afforded 2α,3β-dihydroxylup-12-en-28-oic acid 
(122), 3β-hydroxylup-12-en-28-oic acid (123), oleanolic acid (46), betulinic acid (65), 
mixture of two compounds, arjunolic acid (102) and asiatic acid (103), β-sitosterol (47), 
friedelin (94) and 3β-friedelinol (66). 
List of spectral data and physical properties of compounds 
2α,3β-Dihydroxylup-12-en-28-oic acid (122) 
Colourless crystals; mp 258.2 - 260.4 ˚C; IR (KBr) vmax 3437, 2927, 2856, 1692, 1642, 
1514, 1449, 1377, 1047 cm-1; MS (EI, 70eV), m/z (rel.int. %): 472 [M]+ (8), 454 (5), 248 
(100), 203 (48), 189 (15), 133 (24), 119 (18), 69 (16), 44 (34); HREIMS m/z 472.3549 
(calcd. for C30H48O3, 472.3552);  1H and 13C NMR data: see Table 14.   
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3β-Hydroxylup-12-en-28-oic acid (123) 
Colourless crystals; mp 288.2 - 290.6 ˚C; IR (KBr) vmax 3406, 2922, 2851, 1689, 1639, 
1462, 1383, 1314, 1274, 1038 cm-1; MS (EI, 70eV), m/z (rel.int. %):  456 [M]+ (6), 410 
(14), 248 (100), 203 (54), 189 (34), 133 (40), 119 (26), 69 (26), 41 (34); HREIMS m/z 
456.3588 (calcd. for C30H48O4, 456.3603); 1H and 13C NMR data: see Table 15.   
Mixture of two compounds (102) and (103) 
Colourless crystals;  IR (KBr) vmax 3535, 3372, 2925, 2856, 1694, 1639, 1458, 1389, 
1306, 1270, 1047 cm-1; MS (EI, 70eV), m/z (rel.int. %):  488 [M]+ (4), 470 (3), 452 (10), 
248 (100), 203 (88), 189 (34), 133 (54), 119 (24), 69 (26), 41 (16); HREIMS m/z 
488.3497 (calcd. for C30H48O5, 488.3501) 
Oleanolic acid (46) 
Colourless crystals; mp 196-198˚C; MS (EI, 70eV), m/z (rel.int. %):  456 [M]+ (8), 248 
(100), 207 (25), 203 (34), 189 (15), 133 (14), 119 (18), 69 (16), 44 (34); 1H-NMR δ 0.93 
(3H, s), 0.97 (3H, s), 1.02 (3H, s), 1.04 (3H, s), 1.02 (3H, s), 1.24 (3H, s), 1.30 (3H, s), 
3.30 (1H, ddd, J = 14.6, 4.5 Hz; H-18), 3.44 (1H, dd, J = 11.2, 4.6 Hz; H-3), 5.49 (1H, t, 
J = 3.6 Hz; H-18); 13C-NMR δ 39.0 (C-1), 28.1 (C-2), 78.2 (C-3), 39.4 (C-4), 55.9 (C-5), 
18.8 (C-6), 33.3 (C-7), 39.8 (C-8), 48.2 (C-9), 37.4 (C-10), 23.8 (C-11), 122.6 (C-12), 
144.8 (C-13), 42.2 (C-14), 28.3 (C-15), 23.8 (C-16), 46.7 (C-17), 42.1 (C-18), 46.6 (C-
19), 31.0 (C-20), 34.3 (C-21), 33.2 (C-22), 28.8 (C-23), 16.5 (C-24), 15.6 (C-25), 17.5 
(C-26), 26.2 (C-27), 180.0 (C-28), 33.4 (C-29), 23.8 (C-30).   
Betulinic acid (65) 
Colourless crystals; MS (EI, 70eV), m/z (rel.int. %):  456 [M]+ (36), 438 (12), 411 (6), 
248 (54), 228 (62), 207 (60), 203 (48), 189 (100); 1H-NMR δ 0.83 (3H, s), 1.00 (3H, s), 
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1.06 (3H, s), 1.07 (3H, s), 1.23 (3H, s), 1.80 (3H, s), 3.46 (1H, t, J = 7.2 Hz; H-3); 3.55 
(1H, m; H-19), 4.77 (1H, s; H-30), 4.95 (1H, s; H-30); 13C-NMR δ 39.3 (C-1), 28.3 (C-2), 
78.2 (C-3), 39.5 (C-4), 55.9 (C-5), 18.8 (C-6), 34.8 (C-7), 41.1 (C-8), 50.9 (C-9), 37.5 (C-
10), 21.2 (C-11), 26.1 (C-12), 38.6 (C-13), 42.8 (C-14), 30.3 (C-15), 32.8 (C-16), 56.6 
(C-17), 49.8 (C-18), 47.8 (C-19), 151.3 (C-20), 31.2 (C-21), 37.5 (C-22), 28.6 (C-23), 
16.3 (C-24), 16.4 (C-25), 16.4 (C-26), 14.9 (C-27), 178.8 (C-28), 109.9 (C-29), 19.5 (C-
30).   
 
β-Sitosterol (47), friedelin (94) and 3β-friedelinol (66) 

















Evaluation of Lasiosphaera nipponica (Basidiomycota) for anticancer 
potential and identification of the chemical constituents 
4.1.0 Introduction to Basidiomycota division 
The Basidiomycota Division of the Fungi Kingdom consists of mushrooms, jelly fungi, 
polypores, tooth fungi, crust fungi, chanterelles, coral fungi and puffballs. These fungi 
have fleshy bodies, with many of them edible, while others are very poisonous. 
Mushrooms, puffballs etc. are only a part of the fungus. The main body of a fungus is a 
network of tiny threads, called mycelia, which are usually hidden under tree bark, dead 
leaves or soil.  
 
Edible mushrooms 
The edible pore mushrooms grow in open deciduous woods. The king boletus and many 
other species of the same genus are suitable for food. These mushroom species are 
usually cultivated commercially in dark cellars or specially constructed mushroom houses 
in which the proper humidity and temperature are maintained. The field or garden 
mushroom is a common and widespread species in pastures, grassy areas and manured 
fields. It has the same desirable qualities as the cultivated species. The Chanterelle, a gill 
fungus with a nutlike flavour, has been popular in Europe since ancient times and most 
desirable for eating. The oyster mushroom has a pleasant, oysterlike flavour. This 
mushroom grows in bracketlike clusters on decaying tree trunks. Sulfur mushroom, 
shaggy-mane, giant puffballs, true morels and related species are excellent edible forms.  
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Poisonous mushroom 
The number of poisonous mushroom species is more than 200. Some mushrooms, 
especially amanitas, are extremely poisonous and are often fatal if ingested by humans. 
They contain toxins that destroy cells in the central nervous system, blood vessels, 
kidneys, liver and musculature. Medically, the most important toxins formed by fungi are 
ibotenic acid, muscarine, monomethylhydrazine and the amatoxins and phallotoxins.  
 
Muscarine (125), monomethylhydrazine (126) and ibotenic acid (127)  
Certain mushrooms, particularly Inocybe and Clitocybe species produced muscurine 
(125). It was first isolated from Amanita muscaria. The symptoms of muscarine 
poisoning are a dramatic increase in salivation, lacrimation, perspiration accompanied by 
vomiting, diarrhoea and stomach pains. Death rarely occurs with this poisoning but has 
























Monomethylhydrazine (126) is a toxin produced by the mushroom gyromitrin, Gyromitra 
esculenta. It occurs in the poisonous false morels, which is often confused with true 
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morels [205]. Ibotenic acid (127) is the principal toxin in the fly amanita. It will cause 
damage to the central nervous system. 
 
Amatoxins and phallotoxins 
 
Amatoxins (128, 129) are bicyclic octapeptides. Phallotoxins (130, 131) are bicyclic 
heptapeptides. These are very toxic compounds. Symptoms usually become apparent 8 to 
12 hours or even longer after the mushroom is eaten; death follows in 2 or 3 days. 
Treatment for poisoning by amatoxins is supportive after the mushrooms have been 
cleansed from the gastrointestinal tract. Thioctic acid is administered to individuals 























                                            (128)    α-Amanitin; R = -CH2CONH2 

























                        (130)   Phalloin; R1 = R3 = R4 = Me; R2 = OH 
 
                        (131)   Phallacidin; R1 = CHMe2; R2 = OH; R3 = COOH; R4 = CH2OH 
 
Many other mushrooms are generally avoided because their edibility is doubtful or they 
have a disagreeable odour. The emetic mushroom and its near relatives should be avoided 
[206-211]. 
Puffball fungi 
Puffball fungi come in two different sizes. Puffball of size bigger than a (non-baby) 
potato or a baseball is in the genus Calvatia. The largest ones are members of the genus 
Calvatia. Puffballs of golf ball size or smaller are probably of the genera Lycoperdon or 
Calbovista (Bovista). Puffballs are usually white and round and are attached to the 
ground with little or no apparent stem. Puffballs are edible when young and when still 
fleshy-white within and not edible once they have darkened and begun to go to spore. 
Although many wild mushrooms are delicious and safe to eat, some are not. When cut 
open, the gleba (interior) must not have any sign of yellow, brown, purple but fleshy 
whiteness. It should be regarded as toxic if it is of any colour other than white.  
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4.1.1 Introduction to Lasiosphaera nipponica 
Lasiosphaera nipponica (syn: Lasiosphaera fenzlii, Lasiosphaera fenzlei) belongs to 
Lycoperdaceae family [212]. It is a puffball mushroom commonly known as mabo.  
Kingdom   :    Fungi 
Division    :    Basidiomycota 
Class         :    Gasteromycetes 
Order        :     Lycoperdales 
Family      :     Lycoperdaceae 
Genus       :     Calvatia 
Species     :     Lasiosphaera nipponica (syn: Lasiosphaera fenzlii, Lasiosphaera fenzlei) 
Chinese name   :   Mabo 
English name   :    Puffballs 
Pharmaceutical name/ Latin name   :   Lasiosphaera seu Calvatia 
 
It was reported that the water extract of L. nipponica, showed complete inhibition of 
HIV-1 induced CPE in MT-4 cells and the minimum concentration required was about 
250 μg /mL [212]. It has been used in Japanese and Chinese folk medicine as a 
haemostatic [213]. The cytotoxicity of this mushroom extract has not been reported so far. 
Further, there has been only one publication describing its chemical constituents [214]. 
The present study was undertaken to evaluate the sub-fractions of the hexane extract of 
this fungus for cytotoxic activity against P338 (Murine lymphocytic leukaemia), HL60 
(Human leukaemia), MCF7 (Human breast cancer), HepG2 (Hepatocellular carcinoma) 
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and J82 (Bladder transitional carcinoma) cancer cell lines and to identify the chemical 
constituents of the fractions.  
 
4.2.0 Results and Discussion 
The hexane extract was pooled into six fractions. Three pure compounds were obtained 
from three of the six fractions, one compound from each fraction. The pure compounds 
isolated are characterised as ergosterol peroxide (132), hexadecanoic acid (133) and 
octadecanoic acid (134) by spectroscopic means. Three other Fractions A-C, were 
screened against murine and human cancer cell lines and the results are given in Table 17.   
 
Table 17 
Cytotoxicity (IC50 values) of sub-fractions (A-C) of hexane extract of L. nipponica and 
ergosterol peroxide (132) 
_____________________________________________________________ 
                                















A 9.8 18.2 72.6 >100 >100 
 
B 19.4 16.2 >100 64.8 >100 
 
C 25.3 80.6 >100 >100 >100 
 
EP NT 77.0 NT >234 >234 
 
 
P338: Murine lymphocytic leukaemia; MCF7: Human breast cancer; HL60: Human leukaemia; 
HepG2: Hepatocellular carcinoma; J82: Bladder transitional carcinoma; EP = Ergosterol peroxide 
(132); NT- Not Tested; No. of replicates, n = 8 for each concentration; 6-Mercaptopurine (6MP) 
was used as positive control for P388 cancer cell lines; Doxorubicin was used as positive control 
for MCF7 cancer cell lines; IC50 values are in μg/mL; IC50 values less than 30 μg/mL are 
considered active. For the pure compound, ergosterol peroxide (132), the IC50 values are 




Fraction A showed very good activity against P388 cancer cell lines with IC50 value of 
9.8 μg/mL and good activity against HL60 with IC50 value of 18.2 μg/mL, but was 
inactive against MCF7, HepG2 and J82 cancer cell lines. It showed IC50 value 72.6 
μg/mL against MCF cancer cell lines and it was >100 μg/mL against both HepG2 and J82 
cancer cell lines, the highest concentration tested. Fraction B showed good activity 
against P388 and HL60 cancer cell lines with IC50 values of 19.4 and 16.2 μg /mL, 
respectively but was inactive against MCF7, HepG2 and J82 cell lines; it showed IC50 
value 64.8 μg/mL against HepG2 cancer cell lines and it was >100 μg/mL against both 
MCF7 and J82 cancer cell lines. Fraction C showed only a moderate activity against 
P338 with IC50 value of 25.3 μg/mL but was inactive against other cell lines; it showed 
the IC50 value 80.6 μg/mL against HL60 cancer cell lines and it was >100 μg/mL against 
both MCF7, HepG2 and J82 cancer cell lines. All the three fractions were subjected to 
GC-MS analysis for their chemical constituents. Fatty acids, esters of fatty acids and 
aromatic compounds were identified. The chemical constituents of the individual fraction 
are given in Tables 18, 19 and 20. Plasticizers may contaminate solvents, filter papers, 
plastic apparatus and chromatographic stationary phases stored in plastic containers. 
Phthalate esters are the plasticizers most likely to be encountered [215]. Thus, the 







                Table 18 







  Compounds 
1 9.217 Octanoic acid (135) 
 
2 16.911 Tetradecanoic acid (136) 
 
3 19.819 Butyl isobutyl phthalate (137) 
 
4 20.562 n-Hexadecanoic acid (133) 
 
5 22.166 Heptadecanoic acid (138) 
 
6 22.818 11(Z)-Hexadecenoic acid (139) 
 
7 23.280 Methyl octadecanoate (140) 
 
8 24.052 Octadecanoic acid (134) 
 
9 25.286 Ethyl linoleate (141) 
 
10 29.649 Mono(2-ethylhexyl) phthalate (142) 
 
11 29.679 Diisooctyl phthalate (143) 
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               Table 19 
Chemical constituents of Fraction B of hexane extract of L. nipponica. 
 
      
      No 
  Retention    
  time (min) 
              
     Compounds 
1 13.239 Ethyl 9-oxononanoate(144) 
 
 
2 13.350 Ethyl 11(Z)-hexadecenoate ( 145) 
 
 
3 14.032 Ethyl hexadecanoate (146) 
 
 
4 19.778 Dibutyl phthalate (147) 
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                Table 20 
Chemical constituents of Fraction C of hexane extract of L. nipponica. 
 
    
   No 
   Retention   
   time (min) 
    
 Compounds 
 
1 18.224 Diisobutyl phthalate (148) 
 
 
2 19.796 Butyl isobutyl phthalate (137) 
 
 








                           (148)                                                (149) 
 
Hexadecanoic acid (133) and octadecanoic acid (134) 
Hexadecanoic acid (133) and octadecanoic acid (134) were mainly identified from their 
mass spectral data. Both compounds displayed only two peaks at the high-field region in 
the 1H NMR spectrum; one of them was assigned for methyl group while the other one 
was found to be very intense due to all the methylene protons. Octadecanoic (133) and 
hexadecanoic acids (134) were obtained in small quantities and could not be tested for 
their cytotoxic activity. 
Ergosterol peroxide (132) 
Ergosterol peroxide (132) was obtained as colourless crystals with molecular ion peak at 
m/z 428 in its EI mass spectrum.  The NMR spectrum showed the presence of four 
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secondary methyls and two tertiary methyls and one methine attached to hydroxyl 
functionality. The signal at δ 3.96 (1H, m) was due to hydrogen at H-3.  The signals at δ 
5.18 (2H, m, H-22 and H-23), 6.22 (1H, d, J = 8.5 Hz, H-6) and 6.50 (1H, d, J = 8.5 Hz, 
H-7) were assigned to the protons of the double bonds. The 13C NMR gave peak at δ 66.2 
which was due to oxygenated carbon at C-3 position. Another two carbons were also 
oxygenated since they exhibited their chemical values at δ 79.3 and 82.1, respectively. 
These were due to C-5 and C-8 carbons respectively. The chemical shift values at δ 135.0, 
130.5, 135.3 and 132.1 were assigned for C-6, C-7, C-22 and C-23 carbons respectively. 
The mass spectrum gave major fragmentation peaks at m/z 410 [M-H2O], 396 [M-O2] and 
303 [M-side chain]. The peak at m/z 396 was due to loss of two oxygen atoms (peroxide 
moiety) present in the ring B. Comparison of spectral data of ergosterol peroxide have 





                                                            (132) 
 
4.2.1 Evaluation of ergosterol peroxide (132) for anticancer potential  
Ergosterol peroxide (132) was screened for its cytotoxicity against HL60, HepG2 and J82 
cancer cell lines. It showed only a borderline activity against HL60 cancer cell lines with 




Figure 1  
Cytotoxicity (IC50 values) of the pure compound, ergosterol peroxide (132) against HL60 




It showed 8.1% of growth inhibition at a concentratin of 2.34 μM with a standard 
deviation of (SD) ± 4.39. Similarly the growth inhibitions at a concentrations of 23.4, 
56.5, 117.0 and 234.0 μM were respectively, 17.0 (± 2.57), 41.7 (± 3.70), 67.7 (± 3.98) 
and 75.3 (± 2.14) %.  Ergosterol peroxide (132) was inactive towards HepG2 and J82 
cancer cell lines with IC50 value > 234 μM on both cancer cell lines (Table 18). Its 
activity against P388 and MCF7 cancer cell lines were not tested. Literature search 
revealed that ergosterol peroxide (132) showed strong anticomple- mentary activity [219]. 
It showed antitumor activity against MCF7 (Human breast cancer) and Walker 256 
(Carcinosarcoma) cancer cell lines [220,221].  It showed activity against SNU-1 (IC50 = 
8.0 μg/ml), SNU-C4 (IC50 = 67.7 μg/ml), SNU-354 (IC50 = 36.2 μg/ml), Sarcoma-180 
(IC50 = 31.7 μg/ml) cancer cell lines [222]. It markedly inhibited the tumour-promoting 
effect of TPA in 7,12-dimethylbenz[a]anthracene-initiated mice [223]. 
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4.3.0 Experimental 
General experimental procedure was followed elsewhere as described in Chapter 2 
Plant material 
The plant materials were purchased from a local market and a voucher specimen (KMano 
LN2002) was deposited in the Department of Biological Sciences, National University of 
Singapore, Singapore. 
Extraction and Isolation  
The whole plant material of L. nipponica (600g) was crushed into powder and then 
extracted with hexane (3L x 4) at room temperature. Other experimental procedures were 
the same as described in Chapter 2. The extracts were pooled into six fractions. One pure 
compound was obtained from each of the three fractions. They were ergosterol peroxide 
(132), hexadecanoic acid (133) and octadecanoic acid (134). The other three fractions (A-
C) were subjected to GC-MS analysis for the identification of their chemical constituents. 
GC-MS analysis 
Using Nist MS database, Fraction A was analysed for its chemical constituents on an 
Agilent GC-MS instrument with a column having 50 m length x 0.25 μm film thickness. 
The oven temperature was fixed initially at 50˚C for 2 min and then increased by 10˚C 
/min until 180˚C, maintained for 2 min at this temperature and then increased 5˚C /min 
up to 280˚C, which was maintained for a further 3 min. Fractions B and C were analysed 
for their chemical constituents in the same instrument.  The oven temperature was fixed 
initially at 50˚C for 2 min and then increased by 10˚C /min until 180˚C was attained. This 
was maintained for 2 min and then increased by 5˚C /min up to 300˚C and maintained for 
a further 4 min. 
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Cytotoxic assay  
The same procedure was followed as described in Chapter 2. 
Ergosterol peroxide (132) 
Colourless needles, mp 180-181˚C; IR (KBr) νmax 3360, 1460, 1380, 1277, 1040, 1030, 
960, 940 cm-1; MS (EI, 70eV) 428 M+ (22), 410 (M-H2O) (23), 396 (M-O2) (65), 251 
(83), 209 (38), 197 (45), 141 (35) 69 (100); 1H NMR (CDCl3): δ 0.81 (3H, s), 0.82 (3H, d, 
J = 6.8 Hz), 0.83 (3H, d, J = 6.8 Hz), 0.88 (3H, s), 0.94 (3H, d, J =  6.6 Hz), 1.02 (3H, d, 
J = 6.6 Hz), 3.96 (1H, m, H-3), 5.18 (2H, m, H-22 and H-23), 6.22, 6.50 (each 1H, d, J = 
8.4 Hz, H-6, H-7); 13C NMR: δ 34.7 (C1), 30.0 (C2), 66.2 (C3), 36.8 (C4), 79.3 (C5) , 
135.0 (C6),130.5 (C7), 82.1 (C8), 51.0 (C9), 39.3 (C10), 20.6 (C11), 39.3 (C12), 44.5 
(C13), 51.6 (C14), 23.4 (C15), 28.6 (C16), 56.1 (C17), 12.8 (C18), 18.1(C19), 39.6 (C20), 
20.8 (C21), 135.3 (C22), 132.1 (C23), 42.7 (C24), 33.0 (C25), 19.6 (C26), 19.9 (C27), 
17.5 (C28).  
Hexadecanoic acid (133) 
Colourless crystals; MS (EI, 70eV) 256 M+ (95), 227 (24), 213 (70), 185 (38), 171 (35), 
143 (15), 129 (74), 97 (48), 73 (100), 55 (90), 43 (86).  
Octadecanoic acid (134) 
Colourless crystals; MS (EI, 70eV) 284 M+ (100), 241 (52), 213 (10), 185 (42), 157 (8), 








Evaluation of Juglans regia, Houttuynia cordata and a mixture 
containing six herbs for anticancer potential using selected cancer cell 
lines and the chemical constituents of Fagraea fragrans. 
5.1.0 Introduction to Juglandaceae family 
The species belong to Juglandaceae family are mostly trees, rarely shrubs, deciduous, 
with gray or brownish bark. Terminal buds are larger than lateral buds. Leaves are 
alternate (or opposite), aromatic, usually odd, rarely even and pinnately compound. There 
are about 7 genera, 59 species (2 genera, 17 species in the flora). The fruits in 
Juglandaceae are usually hard stone like materials, the nutmeat inside is coverd by a soft 
and fleshy husk [224].  
 
Juglans regia (Common walnut or Persian walnut), Juglans sigillata (Iron walnut),  
Juglans australis (syn: Juglans boliviana) (Argentine walnut), Juglans brasiliensis 
(Brazilian walnut), Juglans californica (California walnut), Juglans jamaicensis (syn: 
Juglans insularis) (West Indies walnut), Juglans major (Heller Arizona walnut), Juglans 
neotropica (syn: Juglans honorei) (Andean walnut), Juglans nigra (Black walnut), 
Juglans olanchana, Juglans peruviana (Peruvian walnut),  Juglans soratensis, Juglans 
steyermarkii (Guatemalan walnut), Juglans venezuelensis (Venezuela walnut), Juglans 
ailantifolia (Japanese walnut or Heartnut), Juglans stenocarpa (Chinese walnut or 
Manchurian walnut), Juglans cinerea (Butternut) etc. are some examples of species 
belong to the Juglandaceae family. 
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5.1.1 Introduction to Juglans regia 
Juglans regia commonly known as walnut (also called English walnut or Persian walnut) 
belongs to the Juglandaceae family. 
 
Kingdom :  Planate 
Division  :  Magnoliphyta 
Class       :  Magnoliopsida 
Order      :  Fagales 
Family    :  Juglandaceae 
Genus     :  Juglans 
Species   :  Juglans regia   
 
There are about 15 edible varieties of walnuts, foremost among which is the common 
walnut. Used since ancient time, the versatile walnut is grown throughout the world. 
Today, this variety is produced mostly in California. Over 98 % of the total U.S. 
commercial crop and two-thirds of the world's commercial walnuts are produced in 
California. Walnuts are available year-round. English walnuts have a thin shell that is 
easily cracked and the curly nutmeat have a sweet flavour. The wood of English walnuts 
is used for furniture, panelling and gunstocks.  
 
Functions of walnut 
The fat in walnut is beneficial to the formation of albumin in the body. In traditional 
Chinese medicine, it is claimed that walnut is good for nourishing the blood and helping 
inspiration to relieve asthma. It is often used with other herbs such as Cortex eucommiae, 
Fructus psoraleae, Astragali complanati, Fructus corni, Radix Ginseng, Armeniacae 
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amarum, Fructus schisandrae, etc. for reinforcing the kidney to keep vital essence. 
Walnut has been used for lumbago due to kidney-deficiency, dizziness, tinnitus (ringing 
ear), tired extremities, insomnia, forgetfulness, spermatorrhoea and frequent urination. 
About 20 g walnut and 20 g black sesame, all fried to a little bit brown, may be eaten at 
bedtime once daily for habitual constipation. Melatonin is present in walnuts and when 
eaten, increase blood melatonin concentrations.  The increase in blood melatonin levels 
correlates with an increased antioxidative capacity [225]. 
 
5.1.2 Previously reported chemical constituents from Juglans regia 
The amount of secondary metabolites differs depending on the development stage. 
Tocopherols were reported as the main constituents [226]. Leaves are rich in mono- and 
sesquiterpenoids. Caryophyllene (150), eudesmol (151) and the phenolic compound, 
eugenol (eugenic acid) (152) have also been reported [227]. 
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Juglone (5-hydroxy-1,4-naphthalenedione) (153), syringaldehyde (154), phenolic acids, 
chlorogenic acid (85), ellagic acid (155), caffeic acid (156), p-coumaric acid (157), 
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Flavonoid glycosides, hydrolyzable tannins together with adenosine and adenine were 
also reported [229,230]. Juglone (5-hydroxy-1,4-naphthoquinone) (153), 2-methyl-1,4-
naphthoquinone (161), 1,4-naphthoquinone (162) and plumbagin (5-hydroxy-2-methyl-
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                                                   (163)  R1 = Me; R2 = OH 
The mature stem bark yielded the yellow coloured alkaloid, berberine (164) [233]. The 
presence of sterols and carbohydrates had been reported [234]. The presence of ascorbic 
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5.1.3 Introduction to Houttuynia cordata (Saururaceae) 
Houttuynia cordata (Saururaceae) is a Chinese herbal medicine. Fresh H. cordata has the 
actions of clearing heat, eliminating toxins, reducing swelling and relieving stagnation. 
However, dry H. cordata has traditionally been used in clinical application instead of the 
fresh counterpart [236]. It was reported that a hot water extract of a mixture of tea leaves, 
spearmint leaves and H. cordata leaves was effective in preventing mucosal 
inflammation due to influenza, common cold, tonsillitis, etc. 
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 The presence of the flavonol glycosides, rutin, hyperin, afzelin, quercitrin and 
isoquercitrin was identified through HPLC analysis [237]. 3-Decanoyl-6-nonylpyridine 
(166) together with several 1,4-dihydropyridine alkaloids were isolated [238]. 
Aristolactam AII (167), cepharanone B (168), piperolactam A (169) and 
norcepharandione B (170) have been isolated from H. cordata. Some of them exhibited 
significant cytotoxicity against A549, SKOV3, SKMEL2, XF498 and HCT5 human 
















                           (166)                        (167)  R1 = OMe; R2 = OH                     (170)       
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                                                            (169)  R1 = OH; R2 = OMe 
The extract of H. cordata inhibited the growth of influenza virus in cultures. Methyl n-
nonyl ketone (171) n-decylaldehyde (172) and n-dodecylaldehyde (173) were identified 
as antiviral substances. 
MeCO(CH2)8Me          Me(CH2)8CHO         Me(CH2)10CHO                                











5.1.4 Introduction to mixture of six herbs 
 
The mixture of six herbs included Stephania venosa (Menispermaceae) 10.5 %, 
Stephania glabra (Menispermaceae) 8.5 %, Stephania suberosa (Menispermaceae) 3.5 %, 
Hedychium coronarium (Zingiberaceae) 20.0 %, Zingiber officinale (Zingiberaceae) 35.5 
% and Curcuma amada (Zingiberaceae) 22.0 %. 
Stephania venosa 
 
Several alkaloids have been reported from S. venosa including kamaline (174) 
tetrahydropalmatine (gindarine) (175) and N-carboxamidostepharine (176) [240,241].  
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Crebanine, dehydrocrebanine, tetrahydropalmatine, kikemanine, liriodenine, 
oxocrebanine, acetylsukhodianine, ayuthianine (177), sukhodianine (178), 
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Gindarine, an alkaloid obtained from S. glabra, had slight and variable actions on 
systemic arterial blood pressure, heart rate, cardiac contractility and skeletal muscle.  It 
was devoid of surface anesthetic activity, but produced conduction and infiltration 
anesthesia. It did not possess antibacterial property [244].  Bisbenzylisoquinoline alkaloid 
(179), cycleanine, capaurine, corynoxidine and tetrahydroprotoberberine were isolated 
from the rhizomes of S. glabra.  Tetrahydropalmatine, corydalmine, stepholidine, the 
proaporphine alkaloids, pronuciferine, stepharine, the quaternary protoberberine salts, 
palmatine, dehydrocorydalmine, jatrorrhizine and stepharanine were also reported from 

















A promorphinane alkaloid, stephaphylline (180), along with hasubanane, delavaine, 
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Several protoberberines were reported from S. suberosa root extracts. They were 
tetrahydrostephabine, stephabinamine (182), stephabine, 8-oxypseudopalmatine, trans-
xylopinine N-oxide and cis-xylopinine N-oxide. Other alkaloids, tetrahydropalmatine, 
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tetrahydropalmatrubine, stepholidine, kikemanine, capaurimine, coreximine, 










                                                                  (182)  
 
Bisbenzylisoquinoline alkaloids, (+)-2-norcepharanthine (183), cepharanthine, 
strephasubine, norstrephasubine and stephasubimine were also obtained from S. suberosa 














Farnesane-type sesquiterpenes, labdane-type diterpenes, hedychilactones, hedychiols 
were isolated from the methanolic extract of the fresh rhizomes of H. coronarium 
[249,250]. Labdane-type diterpenes, coronarin A, B, C and D (184-187) were isolated as 
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Zingiber officinale   
 
Zingiber officinale (Ginger) has been widely used as a dietary spice as well as in 
traditional medicine.  The rhizome of ginger contains pungent vanillyl ketones, including 
6-gingerol (188) and 6-paradol (189) and has been reported to possess a strong anti-
inflammatory activity. It was also reported that the pungent vanilloids found in ginger 
possess potential chemopreventive activities. These vanilloid structures were found in 












                         (188)                                                                    (189) 
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Ginger is a natural dietary component with antioxidant and anticarcinogenic properties.  
The effect of ginger on the initiation and post-initiation stages of 1,2-dimethylhydrazine 
(DMH)-induced colon carcinogenesis in male Wistar rats was reported. The number of 
tumors as well as the incidence of cancer was significantly decreased on treatment with 
ginger [256]. 
 
Curcuma amada  
Extracts of fresh or dried Curcuma amada, preferably the rhizomes have medicinal 
properties. They can be used as immunosuppressants and for the alleviation of pain.  
Specifically, they are used for preparing medicaments for the treatment or prevention of 
hypersensitivity diseases. 









Curcumin (190), an orange-yellow colouring compound present in rhizomes, has long 
been known to possess antioxidant property.  β-Sitosterol and α-pinene were also 
reported as the main constituents from the rhizomes of C. amada [257]. 
 
5.1.5 Introduction to Fagraea fragrans  
Fagraea fragrans belongs to the Loganiaceae family. The vernacular name for this plant 
is Tembusu Padang. The tree is impressive in its 40 m or so height and single trunk with 
deeply fissured bark. Branches arise from the main trunk and grow upwards. The leaves 
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are simple, elliptical and narrow towards the tip. Flowers are large in bunches, creamy 
white, turning yellow. They are very fragrant, especially during the late evenings, for 
they attract night-flying moths which help their pollination. The tree flowers twice a year, 
towards the middle and the end of the year. Fruits are small, roundish berries, found in 
small bunches, turning orange then scarlet with maturity [258]. 
 
A thorough literature search indicated that the plant was not extensively studied, both 
phytochemically and pharmacologically. There was a report which described the isolation 
of an alkaloid, gentianine (191), from the leaves and fruits of this plant. The alkaloid 
content of the plant showed marked seasonal variation.  The yield of alkaloid from the 
leaves was highest (0.32%) at the beginning of the flowering season (May-June) and 
lowest (0.005%) after fruiting had occurred (October-November).  The ripe fruits 





                                                                (191) 
 
There was another report which described the pharmacological effects of the gentianine 
(191) on experimental animals. Gentianine (191), when administered orally to rats at 
doses of 50 and 100 mg/kg, produced 20 and 30%, analgesia, respectively.  It had no 
antipyretic activity or diuretic effect in rats, no hypoglycemic activity in guinea pigs and 
no cardiovascular or central nervous system effects on anesthetised cats [260]. 
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5.2.0 Results and Discussion 
Juglans regia 
The seeds of J. regia were extracted with chloroform; an oily liquid and residue was 
obtained. Five sub-fractions were obtained from this residue. Four of them contained a 
gum like material; we were unable to isolate any pure compounds from these fractions. 
However, these four sub-fractions and the original residue were screened for their 
cytotoxicity against P388, HL60, LL2, MCF7 and HepG2 cancer cell lines. They showed 
no activity against all these five cancer cell lines tested even at a concentration of 100 
μg/mL. The fifth fraction was not tested for its cytotoxicity since it was obtained in small 
quantity. However, a known compound, β-sitosterol (47) was isolated from this fraction. 
This compound had already been isolated several times earlier and the identity was 
confirmed through a direct comparison with the original spectra.  
HO  
                                                                      (47) 
 
 
The oily liquid was subjected to GC-MS analysis, for the identification of its chemical 








Chemical constituents of the oily liquid obtained from seeds of Juglans regia, identified 
by GC-MS analysis. 
 
 
Peak           Rt          Area               Library    
                (min) 
 
 1               8.29          1.26             n-Hexanoic acid   
 
 2               8.75          4.70             Ethyl hexadecanoate 
 
 3              10.30          2.77            Methyl l9,12-octadecadienoate 
 
 4              10.468       16.55           Methyl 8(E)-octadecenoate 
 
 5              11.29           9.30           9,12 (Z,Z)-Octadecadienoic acid  
 
 6              11.75         29.93            Ethyl linoleate  
 
 7              11.96          6.59             Ethyl oleate 
 
 8              21.30          4.98             Unknown 
 
 9              26.88          3.46            γ-Tocopherol 
 
10             30.19        16.95             Unknown 
 
11             31.08          3.51             Unknown 
 




The crude extract, ethyl acetate, butanol and alcohol-water fractions of H. cordata were 
screened for their cytotoxicity against P388, HL60, LL2, MCF7 and HepG2 cancer cell 
lines. They showed no activity against all these five cancer cell lines tested even at a 
concentration of 70.0 μg/mL.  Though some alkaloids isolated from this plant showed 
significant activity against A549, SKOV3, SKMEL2, XF498 and HCT5 human tumour 
cell lines [255], in the present study the crude extract and its fractions showed no activity 
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against the five cancer cell lines tested. The reason for this may be the chemical 
constituents of the crude extract or its fractions may not induce cytotoxicity against P388, 
HL60, LL2, MCF7 and HepG2 cancer cell lines or the active constituents may exist in 
small amounts and under the experimental condition the active constituents are 
insufficient to induce cytotoxicity. 
 
Mixture of six herbs 
The alcoholic extract of mixture of herbs was screened against HL60, P388, MCF7, J82 
and HepG2 cancer cell lines. It showed no activity against all the five cancer cell lines 
tested even at a concentration 100 μg/mL, the highest concentration tested. It showed 
growth inhibition of 2.3, 5.0, 7.8 and 10.2 %, respectively at 10, 25, 50 and 100 μg/mL 
concentrations on P388 cancer cell lines. It showed growth inhibition of 4.5, 7.8, 12.2 and 
15.4 %, respectively at 10, 25, 50 and 100 μg/mL concentrations on J82 cancer cell lines. 
It showed growth inhibition of 1.5, 5.4, 9.8 and 20.0 %, respectively 10, 25, 50 and 100 
μg/mL concentrations on HL60 cancer cell lines. It showed growth inhibition of 2.2, 3.5, 
4.2 and 9.4 %, respectively at 10, 25, 50 and 100 μg/mL concentrations on HepG2 cancer 
cell lines.  It showed growth inhibition of 7.2, 13.8, 24.6 and 39.2 %, respectively at 10, 
25, 50 and 100 μg/mL concentrations on MCF7 cancer cell lines.   
 
Of the six herbs, Z. officinale was reported to have a variety of biological activity 
including anticancer activities. H. coronarium also showed anticancer property; some 
labdane-type diterpenes were identified as cytotoxic principles [269-271]. For the other 
four herbs, no reports were seen concerning their cytotoxicity. In the present study the 
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crude extract showed no activity against five cancer cell lines. It was due to the same 
reason as cited earlier that the chemical constituents of the extract may not induce 
cytotoxicity against P388, HL60, J82, MCF7 and HepG2 cancer cell lines or the active 
constituents may exist in small amounts and under the experimental condition these 





The crude extract of F. fragrans was analysed for its chemical constituents using GC-MS 
analysis. Several aromatic compounds, a few fatty acids and their esters and a few sterols 










































1  8.71 2.240 Benzoic acid 
2 13.72 0.793 E-Stilbene 
3 14.63 0.319 4-Hydroxy-3,5-dimethylbenzaldehyde 
4 14.67 0.478 Unknown 
5 14.87 0.221 4-Hydroxy-3,5-dimethoxybenzaldehyde 
6 15.21 0.457 4-Hydroxy-3,5-dimethoxybenzyl alcohol 
7 15.48 0.458 4-Hydroxy-2-methoxycinnamaldehyde 
8 15.60 9.647 Unknown 
9 17.19 0.326 Unknown 
10 18.10 0.543 4-Hydroxy-3,5-dimethoxycinnamaldehyde 
11 18.29 7.065 Unknown 
12 18.46 1.407 n-Hexadecanoic acid 
13 18.71 0.531 Unknown 
14 20.42 0.310 Methyl 9,12-octadecadienoate 
15 21.03 4.595 9,12 (Z,Z)-Octadecadienoic acid  
16 21.15 3.244 Unknown 
17 21.54 0.784 Octadecanoic acid 
18 26.13 0.354 Unknown 
19 31.57 3.097 Unknown 
20 33.78 1.866 Unknown 
21 34.02 0.435 Stigmastan-3,5,22-triene 
22 35.15 0.295 Unknown 
23 35.42 3.202 Unknown 
24 35.67 3.074 Unknown 
25 35.92 24.565 Stigmasterol 
26 36.20 11.767 Sitosterol 
27 36.62 12.143 Unknown 
28 37.33 2.468 Unknown 
29 37.68 1.376 Unknown 
30 38.13 1.211 Unknown 
31 38.33 0.726 Unknown 
 
Although GC-MS analysis can give quick and accurate results of the existence of known 
compounds, it is unsuitable for the identification of less familiar compounds. The 
chloroform fraction obtained from the crude extract was chromatographed on a silica gel 
column using hexane solvent and eluted with solvents of increasing polarity. The first 
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few fractions obtained were either oily liquid or solid materials. However, all those 
fractions, when analysed by TLC, had showed no significant spots and were not analysed 
any further. Following this, stigmasterol (192) (62 mg) and β-sitosterol (47) (ca.6 mg), 
were isolated from two fractions, one compound from each fraction.   
 
Characterisation of stigmasterol (193) and β-sitosterol (47) 
β-Sitosterol was isolated several times earlier and the structure was confirmed by direct 
comparison with the original spectra. Refer to Chapter 2 for the interpretation. 
HO  HO  
                                 (47)                                                           (192) 
Stigmasterol (193) was obtained as colourless crystals. The mass spectrum gave a 
molecular ion peak at m/z 412, which determined the molecular formula C29H48O. The 1H 
NMR spectrum showed four signals which were well separated and with high shift values. 
One of the signals resonated at δ 3.52, which corresponds to H-3. Another signal was 
observed at δ 5.35 (br, d, J = 5.4 Hz), which was due to ring olefinic hydrogen, H-6. Two 
other peaks resonated at δ 5.13 (dd, J = 8.4, 5.4 Hz) and 5.00 (dd, J = 8.4, 1.5 Hz); these 
are due to the side chain olefinic protons at H-22 and H-23, respectively. The 13C NMR 
spectrum gave a peak at δ 72.0 that indicated the presence of a hydroxyl group. Further, 
two peaks were resonated at δ 140.8 and 121.8, respectively. These values showed the 
presence of a double bond and were assigned to C-5 and C-6 carbons, respectively. Two 
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other peaks also resonated at the olefinic region, one at δ 138.3 and another at δ 129.7, 
respectively. These were due to double bond at the side chain between C-22 and C-23, 
respectively. Comparison of its spectral data with those reported in the literature showed 
good agreement [126,245]. Original spectrum of 1H NMR was printed in the literature 
[261]. Stigmasterol (192) is a phytosterol with a wide range of metabolism and 




















General experimental procedures were followed as described in Chapter 2. 
Cytotoxic study  
The same procedure was followed as described in Chapter 2. 
 
Plant material, Extraction and Isolation  
Juglans regia 
The seed material was purchased from a local market and a voucher specimen (KMano 
SJ 2003) was deposited in the Department of Biological Sciences, National University of 
Singapore, Singapore. 
 
The seeds were extracted with chloroform and this procedure was repeated several times. 
The extract was kept in a china-dish and left to stand for a few days. An oily liquid was 
separated out and removed by simple decantation. The residue thus obtained was 
chromatographed over a silica gel column, using hexane and eluted with solvents of 
increasing polarity. Fractions were collected and monitored as per the procedure 
described in the Chapter 2. After collection of several fractions, β-sitosterol was obtained 
along with impurities. Further purification followed by recrystallisation with acetone 
yielded the pure compound (c.a. 3 mg).     
 
Using Nist MS database, the oily liquid was analysed for its chemical constituents on an 
Agilent GC-MS instrument with a column having 50 m length x 0.25 μm film thickness. 
The oven temperature was fixed initially at 150˚C for 20 min and then increased by 10˚C 
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/min until 200˚C, maintained for 5 min at this temperature and then increased by 5˚C/min 
up to 290˚C, which was maintained for a further 10 min. 
β-Sitosterol (47) For mp, IR, MS, 1H NMR and 13C NMR; refer to Chapter 2. 
 
 
Houttuynia cordata and mixture of herbs 
 
H. cordata crude extract and their fractions and the mixture of six herbs powder weighing 
about 250 g were provided by Assoc. Prof. Tan, Kwong Huat, Benny, Traditional 
Medicine & Natural Products Research Laboratory, Department of Pharmacology, NUS. 
The mixture of herbs powder was extracted with 80% alcohol. Rota-vapour was used to 
remove solvents as much as possible at the first followed by the use of a freeze 
dryer/lyophilizer. The crude extract thus obtained was used for cytotoxic screening.  
Fagrae fragrans 
The stem-bark of the plant material was collected in Singapore and identified by 
Associate Prof. Hugh Tan Tiang Wah, Dept. of Biological Sciences, NUS and Chua 
Keng Soon, Senior Laboratory Officer (RMBR), Herbarium, NUS. A voucher specimen 
(KM20041122) was deposited in the herbarium, Department of Biological Sciences, 
National University of Singapore, Singapore. 
 
A branch weighing about 25 kg was cut and chopped into small pieces. The air-dried 
material was extracted with methanol. The methanol extract was chromatographed using 
hexane solvent but we faced problems for further elutions. Actually, the solvent did not 
flow through and latex-like material was initially observed. Thus we recovered the 
sample from the column. The extract was then suspended in methanol/water (8:2) and 
partitioned between this solvent mixture and chloroform. This partition was repeated 
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several times and the chloroform fraction was collected separately. The methanol/water 
fraction was obtained as gum-like material and was discarded. Solvent was removed from 
the chloroform fraction using a Rota-vapour and the residue thus obtained was 
chromatogaphed again using hexane and then eluted with solvents of increasing polarity.  
β-Sitosterol (47)  
For mp, IR, MS, 1H NMR and 13C NMR, refer to Chapter 2. 
Stigmasterol (5,22-Stigmastadien-3β-ol) (192) 
Colourless flakes; mp.166.2-168.7˚C; MS (EI, 70eV), m/z (rel.int. %): 412 [M]+ (96), 382 
(72), 369 (30), 351 (48), 255 (100), 231 (32), 173 (34), 145 (78),133 (60), 107 (74), 83 
(84), 55 (62); 1H NMR (CDCl3): δ 1.08 m, Hα, 1.84 m, Hβ (H-1), 1.83 m, Hα, 1.51 m, 
Hβ (H-2), 3.51 (1H, m, H-3), 2.30 m, Hα, 2.23 m, Hβ (H-4), 5.34 (1H, m, 5.4 Hz, H-6), 
1.50 m, Hα,1.97 m, Hβ (H-7), 1.46 m (1H, H-8), 0.94 m (1H, H-9), 1.50 m, Hα and Hβ 
(2H, H-11), 1.19 m, Hα, 2.00 m, Hβ (H-12), 1.01 (1H, H-14), 1.56 m, Hα, 1.06 m, Hβ, 
(H-15), 1.72 m, Hα, 1.28 m, Hβ, (H-16), 1.15 (1H, H-17), 0.70 (3H, s, H-18), 1.01 (3H, s, 
H-19), 2.06 m (1H, H-20), 1.03 (3H, d, J = 6.4 Hz, H-21), 5.17 (1H, dd, J = 15.2 Hz, H-
22), 5.04 m (1H, dd, J = 8.6 Hz,  H-23), 1.54 m (1H, H-24), 1.55 m (1H, H-25), 0.85 (3H, 
d, 6.8 Hz, H-26), 0.80 (3H, d, J = 6.4 Hz, H-27),1.43 m (1H, H-28), 0.81 (3H, t, J = 6.6 
Hz, H-29); 13C NMR (CDCl3): δ 37.6 (C-1), 31.9 (C-2), 72.0 (C-3), 42.5 (C-4), 140.8 (C-
5), 121.8 (C-6), 32.1 (C-7), 32.2 (C-8), 50.5 (C-9), 36.5 (C-10), 21.2 (C-11), 40.0 (C-12), 
42.2 (C-13), 57.1 (C-14), 24.5 (C-15), 28.9 (C-16), 56.3 (C-17), 12.2 (C-18), 19.5 (C-19), 
40.4 (C-20), 21.4 (C-21), 138.3 (C-22), 129.7 (C-23), 51.5 (C-24), 32.2 (C-25), 21.2 (C-










P. bistorta was screened for its cytotoxicity against selected cancer cell lines, assessed for 
its toxicity on experimental animals (Swiss albino mice) and investigated for their 
chemical constituents. Both chloroform and hexane fractions and a few of their their sub- 
fractions showed moderate to very good activity against P388, HL60 and LL2 cancer cell 
lines. We found that the LD50 value of crude extract was 150 mg/kg of body weight of 
mice and that of chloroform extract was 200 mg/kg of body weight of mice; while, the 
hexane extract has an LD50 value >200 mg/kg of body weight of mice. This is the first 
such report in this plant. Our investigations on the chemical constituents of this plant 
revealed the presence of three new and two known cycloartane-type triterpenoids, two 
known pentacyclic triterpenoids and three steroids. Two of the cycloartane triterpenoids, 
24-methylenecycloartanone (97) and 24(E)-ethylidenecycloartan-3α-ol (98), were 
isolated from active fractions. These two compounds could not be tested for their 
pharmacological activity since they were obtained in small quantities. One of the new 
compounds, 24(E)-ethylidenecycloartanone (93), was screened for its cytotoxicity against 
a panel of cancer cell lines, but did not show any significant activity.  
 
Some cycloartane-type triterpenoids, mostly in the form of saponins or with several 
functional groups, showed cytotoxic acitivities against several cancer cell lines, viz. 
HepG2 (Hepatocellular carcinoma cells), HL60 (Human leukaemia cells), KB Cells, 
A2780 (Ovarian cancer cells), 26-L5 (Murine colon cells), HSC2 (Human oral squamous 
cell carcininoma), U251 (CNS), PC3 (Prostate cancer cells), HCT15 (Colon carcinoma 
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cells), MCF7 (Human breast cancer cells), K562 (Leukaemia) etc. [135-144]. These 
results indicated that some cycloartane-type compounds are cytotoxic against some 
cancer cell lines. However, the new compound, 24(E)-ethylidenecycloartanone (93), 
though it is a cycloartane-type compound, did not show any activity on a panel of cancer 
cell lines. The new compound, 24(E)-ethylidenecycloartanone (93), has only a ketone 
functional group and one double bond. The lack of functionality would be a probable 
reason for its inactivity on the cancer cell lines tested or it may not induce any inhibition 
on the cancer cell lines selected for the testing. Synthetic analogues of this new 
compound, 24(E)-ethylidenecycloartanone (93), can be prepared and could be tested for 
their cytotoxic effects. The hexane and chloroform factions can also be further 




The chloroform extract of the stem-bark of E. grandis was investigated for its chemical 
constituents. A new pentacyclic triterpenoid, 2α,3β-dihydroxylup-12-en-28-oic acid (122), 
a rarely encountered triterpenoid, 3β-hydroxylup-12-en-28-oic acid (123) and some 
known pentacyclic triterpenoids, were isolated. From this result, we understand that E. 
grandis is rich in pentacyclic triterpenoids. Pentacyclic triterpenoids, in general, exerted a 
variety of biological and pharmacological effects. To the best our knowledge, not only 
the chemical constituents but also the pharmacology of this plant material has not been 
extensively studied so far. Thus, other parts of the plant material may be investigated 
both phytochemically and pharmacologically. 
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Lasiosphaera nipponica 
The present study was a small scale screening of the fungus, L. nipponica. The sub-
fractions of the hexane extract of L. nipponica showed very good to good activity against 
P388 and HL60 cancer cell lines. This is the first report on cytotoxicity of this fungus 
material. Therefore, the sub-fractions of the extract may be subjected to further in-vivo 
and/or other in-vitro pharmacological assays eg. annexin V, caspase-3, etc. One pure 
compound, ergosterol peroxide (132) was isolated along with fractions that showed 
borderline activity against HL60 (Human leukaemia cancer cell lines). Ergosterol 
peroxide (132) showed strong anticomplementary activity [223]. It showed antitumour 
activity against MCF7 (Human breast cancer cell lines) and Walker 256 (Carcinosarcoma 
cell lines) [224,225]. It also showed activity against SNU-1 (IC50 = 8.0 μg/ml), SNU-C4 
(IC50 = 67.7 μg/ml), SNU-354 (IC50 = 36.2 μg/ml) and Sarcoma-180 (IC50 = 31.7 μg/ml) 
cancer cell lines [226]. It markedly inhibited the tumor-promoting effect of TPA in 7, 12-
dimethylbenz[a]anthracene-initiated mice [227]. Ergosterol peroxide (132) is one of the 
major constituents in this fungus material and therefore more ergosterol peroxide (132) 
may be obtained for in vivo pharmacological studies. As the chemical constituents of this 




This plant material is also not extensively studied, both phytochemically and 
pharmacologically. The stem-bark of the plant material was investigated for its 
phytochemical constituents. When extracted with methanol, a latex-like material was 
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obtained. After solvent-solvent partition followed by purification, only two known 
steroids were isolated. Other parts of plant material may be investigated both 
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